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Chronic kidney disease (CKD) is a contributor to morbidity and mortality in dogs. The 
general aim of this thesis was to increase knowledge regarding pathophysiologic 
mechanisms and early diagnosis of canine CKD by identifying dogs with increased risk 
of disease, and by exploring the value of various biomarkers in blood and urine. 
Dogs are comparably commonly diagnosed with kidney-related disease (KD), but 
neither incidence nor mortality rates of KD have previously been reported. In paper I, 
incidence and mortality rates of KD were calculated in a population of >600,000 dogs. 
The total incidence rate of KD in this population was 15.8 cases per 10,000 dog years at 
risk (DYAR, representing one dog insured for one year). The mortality rate of KD was 
9.7 deaths per 10,000 DYAR. The breeds with the highest incidence rates in this study 
were the Bernese mountain dog, miniature schnauzer and boxer. The Swedish elkhound, 
Siberian husky and Finnish spitz were the breeds with the lowest rates. 
Increased concentrations of two cardiovascular biomarkers, B-type natriuretic peptide 
(NT-proBNP) and cardiac troponin I (cTnI), have been reported in dogs with decreased 
renal function. The aim of paper II was to investigate if NT-proBNP and cTnI accumulate 
in the circulation of dogs with CKD, as GFR declines. The results did not support passive 
accumulation, and the conclusion was that these markers identify increased blood volume 
and damage to cardiac cells, respectively, in dogs with CKD.  
Symmetric dimethyl arginine (SDMA) and cystatin C are two potential biomarkers of 
decreased GFR in the dog. In paper III, the aim was to investigate overall diagnostic 
value of SDMA and cystatin C as markers of decreased GFR, compared to the current 
marker, creatinine. The overall value of SDMA was equivalent to that of creatinine, but 
cystatin C performed less well as a marker of decreased renal function in this study.  
In human medicine, a specific urinary peptide pattern that detects CKD has been 
developed. Changes in the canine urinary peptide pattern may represent a completely 
new opportunity for early diagnosis of canine CKD as well. In paper IV, a CE-MS-based 
urinary peptidome model, 133P, was constructed and shown to be able to discriminate 
healthy dogs from dogs with CKD in a separate cohort. This model, although in need of 
further investigation and validation, represents an exciting new diagnostic modality in 
that it may prove to be able to detect chronic progressive CKD in a single urine sample.  
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nephrology 
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Abstract 
  
Kronisk njursjukdom (CKD) hos hund är en allvarlig sjukdom som kan ha många olika 
underliggande orsaker. De övergripande målen med denna avhandling var att öka 
kunskapen kring patofysiologi och tidig diagnostik av CKD hos hund. I studie I 
sammanställdes data från > 600 000 hundar registrerade hos Agria Djurförsäkring under 
12 års tid. Förekomst av njursjukdom beräknades till ca 16 nya fall per 10 000 hundår 
(ett mått som innebär en hund försäkrad under ett år). Dödlighet till följd av njursjukdom 
uppgick till ca 10 dödsfall per 10 000 hundår. Högst förekomst av njurrelaterad sjukdom 
sågs hos berner sennen, dvärgschnauzer och boxer. Lägst förekomst sågs hos jämthund, 
siberian husky och finsk spets.  
B-type natriuretic peptide (NT-proBNP) och hjärtspecifikt troponin I (cTnI) är två 
sjukdomsmarkörer som kan mätas i blodet och används för att upptäcka hjärt- och 
kärlpåverkan hos hund. Tidigare studier har visat att höga koncentrationer av dessa 
markörer kan ses hos hundar med njursjukdom. Anledningen till detta är inte känd, men 
en passiv ackumulering av NT-proBNP och cTnI i blodet har misstänkts, vilket 
undersöktes i studie II. Resultaten indikerade att en passiv ackumulering av dessa 
markörer inte föreligger hos hund när njurfunktionen minskar. Detta innebär att 
NT-proBNP och cTnI påvisar hjärt- och kärlpåverkan även hos hundar med CKD.  
Symmetric dimethyl arginine (SDMA) och cystatin C utgör två markörer för detektion 
av nedsatt njurfunktion (GFR). I studie III undersöktes det diagnostiska värdet av dessa 
markörer jämfört med den för närvarande vanligaste markören för njurfunktion, 
kreatinin. Det övergripande diagnostiska värdet av SDMA var likvärdigt med värdet av 
kreatinin. Värdet av cystatin C var lägre än det av de båda andra markörerna. För vissa 
hundar finns dock anledning att analysera SDMA eller cystatin C i tillägg till kreatinin. 
I studie IV utvärderades en helt ny metod (kapillär elektrofores och 
masspektometri, CE-MS) för diagnosticering av njursjukdom. Med hjälp av denna metod 
undersöks urinens hela innehåll av peptidfragment. Skillnader i peptidmönster mellan 
sjuka och friska individer undersöktes och en statistisk modell, 133P, för diagnostik av 
CKD konstruerades. Validering av 133P i en separat grupp av hundar med och utan CKD 
visade att modellen kunde särskilja dessa grupper. Urinanalys med hjälp av CE-MS 
behöver valideras ytterligare, men utgör ett potentiellt nytt alternativ för tidig diagnostik 
av CKD hos hund i framtiden.  
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Chronic kidney disease (CKD) is an important contributor to morbidity and 
mortality in dogs. The definition of CKD has changed over time and is not 
clearly established in veterinary medicine. In some companion animal medicine 
textbooks, CKD is defined as presence of functional or structural damage to one 
or both kidneys with a duration of more than three months (Polzin, 2017), which 
is similar to the definition of human CKD (Levey, 2012). Structural damage 
refers to abnormalities of macroscopic or microscopic anatomy. The term “renal 
function” most commonly refers to the glomerular filtration rate, GFR, which is 
considered the best indicator of global renal function. However, the kidneys 
continuously perform other multiple, life essential tasks in order to maintain 
whole-body homeostasis. Tubular actions (reabsorption, secretion, and 
electrolyte and acid-base homeostasis), glomerular filtration barrier integrity and 
different endocrine functions are examples of “renal function”. Serious 
compromise of one or more of these functions may be present without a 
detectable decrease in GFR (Klosterman et al., 2011; McNamara et al., 1989).  
As renal functional mass decreases, multiple systemic negative consequences 
develop. Some of those may also further compromise the kidney. Detection of 
these systemic consequences is important both diagnostically and for optimal 
treatment. In both human and veterinary medicine, CKD is regarded, and often 
described as, a progressive, incurable disease (Jepson & Syme, 2017). This is 
however not true for all dogs that fit the currently used CKD definition. 
There are multiple possible underlying aetiologies of canine CKD. In many 
cases, the initiating cause is not evident, and may no longer be present, at the 
time of diagnosis. Clinical signs of CKD are not pathognomonic and, at least for 
some diseases of the kidney, often do not emerge until comparably late in the 
course of disease, because of the large reserve capacity of these organs.  
In order for dogs to be investigated for CKD, they must be presented to a 
veterinarian by their owner. Awareness among owners and veterinarians of the 
general incidence of CKD and any increased risk of the disease in certain breeds 
1 General background 
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probably increases the opportunity for early diagnosis. Reported prevalence of 
CKD in canine studies varies, depending on the population studied (Sosnar et 
al., 2003; Lund et al., 1999). A reasonable estimate of overall prevalence of 
CKD in the canine population has been suggested to be 0.5-1.5% but there are 
no studies that confirm this statement (Brown, 2007). Because of the insidious 
character of the disease and the commonly delayed diagnosis, estimates of 
prevalence may be falsely low. Breed predisposition to specific diseases of the 
kidney are known for a few breeds and suspected in others, but differences in 
incidence or mortality rates of kidney disease between breeds have previously 
not been investigated.  
Current methods for diagnosis of canine CKD are insensitive, especially for 
some kidney disease manifestations (such as chronic tubulointerstitial disease). 
Many of the diagnostic biomarkers that are used, are also not specific for renal 
dysfunction and damage. Pre-renal and post-renal influences on both GFR and 
proteinuria are examples of states that complicate biomarker use (Tabaru et al., 
1993; Harris & Gill, 1981). Knowledge of renal physiology and pathophysiology 
is required for interpretation of test results. 
Considerable effort is invested in potential new diagnostic methods for a 
number of reasons. A method for early diagnosis of CKD would be of value in 
the work-up of dogs that are presented with clinical signs such as chronic 
unexplained polyuria and polydipsia (PU/PD), or recurrent infection of the 
urinary tract. In both scenarios, subclinical CKD is a plausible differential 
diagnosis that often is difficult to diagnose (or rule out). Also, in breeds of dog 
that are predisposed to CKD of different aetiologies (for which a genetic test is 
not available, such as renal dysplasia), there might be uncertainty regarding 
kidney disease status in a certain young individual intended for breeding. Under 
these circumstances an early, robust method of diagnosis would be highly 
valuable in order to know which individuals not to breed.  
Clinical management of CKD is aimed to resolve (if possible) any identified 
underlying pathology, provide adequate nutrition, slow progression of disease 
and prevent and treat complications associated with decreased renal function 
(Polzin, 2013). Owners of dogs with CKD are often willing to initiate chronic 
treatment in an attempt to prolong life, as long as quality of life is ensured. An 
early diagnosis of progressive disease probably increases the opportunity of 
more effective clinical management (Schievink et al., 2016; Polzin, 2013), 
which may then focus on prolonging time until development of clinical signs.  If 
a positive effect (such as slowing the rate of progression) of specific treatment 
is proven for dogs at the earliest stages of CKD, the value of early diagnosis 
would further increase. In order to evaluate that, however, dogs need to be 
diagnosed early in the disease process. A balance between “need and actions” is 
17 
 
important in this respect, because a diagnosis is only relevant if the disease is 
anticipated to generate morbidity in the future. 
The ultimate, not yet accomplished, goal of CKD treatment in dogs, as well 
as in people, is to completely halt or even reverse disease progression (Tampe & 
Zeisberg, 2014). Increased knowledge regarding biological processes 
underlying CKD progression and the associated renal fibrosis is needed in order 
to reach this treatment goal in the future. Consequently, a continued effort to 
find new, robust methods of early diagnosis of CKD in dogs is desirable. 
 
 
 
Joy, Australian shepherd, 2007-2016. One of the dogs that contributed with valuable data to this 
thesis. (Courtesy of Steff Krusengren). 
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Anatomically, the kidneys consist of an outer region, the cortex covered by a 
capsule, and an inner region, the medulla, which embraces a centrally situated 
pelvis (Fig 1). The kidneys are responsible for many different aspects of 
homeostasis and may be divided into three functionally different compartments; 
the glomerular, the tubular and the interstitial compartments. Some authors also 
consider the renal vasculature a fourth compartment. The principal function of 
the kidney is to clear unwanted substances from the body, either by glomerular 
filtration, or by active secretion into the urine by the tubular system, or both. 
Examples of unwanted substances are end-products of metabolism such as 
inorganic phosphate and potassium and exogenous substances such as drugs and 
toxins. The kidneys are responsible for fluid-, acid/base- and electrolyte 
homeostasis as well as blood pressure regulation. Also, the kidneys perform 
multiple endocrine functions: Interstitial fibroblasts produce erythropoietin 
(EPO), a hormone needed for production of red blood cells (Kurtz et al., 1989). 
The juxtaglomerular cells within the kidney produces the hormone renin in 
response to reduced circulating volume (Kurtz, 2011). Renin initiates a cascade 
called the renin-angiotensin-aldosterone system (RAAS), aimed at sodium and 
water retention. Also, the inactive metabolite 1, 25 dihydroxycholecalciferol is 
transformed into calcitriol, “activated” vitamin D, by 1α-hydroxylase, an 
enzyme of which the kidney is the most abundant source. 
Each canine kidney contains several hundred thousand functional units called 
nephrons. Every nephron consists of a renal corpuscle (glomerulus, mesangium 
and Bowman´s capsule, Fig 2) and a tubular system, through which urine is 
transported towards the renal pelvis. The tissue between nephrons and vessels, 
the interstitium, acts as a support structure for cells. It consists of a highly 
charged extra-cellular matrix (ECM), which is most prominent in the renal 
medulla. Proteases (for example matrix metalloproteinases, MMPs) and their 
inhibitors maintain the delicate equilibrium between ECM synthesis and 
2 Kidney anatomy and physiology 
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degradation (Aresu et al., 2011). It is now recognised that the ECM, in addition 
to its supportive function, also is highly active in cell signalling (Seikrit et al., 
2013; Rozario & DeSimone, 2010).  
Through the renal arteries, the kidneys receive a sizable part (approximately 
20%) of cardiac output, especially considering the small size (about 1% of body 
mass) of these organs. After flowing through interlobar, arcuate and interlobular 
arteries, blood enters the glomerular tuft, a web of fenestrated capillaries, where 
filtration takes place. Mesangial cells, which have contractile properties and are 
thought to contribute to the glomerular filtration function, provide structure for 
the glomerular capillary loops (Schlondorff, 1987). Glomerular plasma flow and 
intraglomerular pressure are fine-tuned by hemodynamic actions of the afferent 
and efferent arterioles at both ends of the glomerular tuft (Brown et al., 1990). 
Blood is filtrated through three layers; the fenestrated endothelium, the 
glomerular basement membrane and the epithelium, through the slit diaphragm 
of podocytes (Deen et al., 2001). 
 
Fig 1. Macroscopic anatomy of the kidney. (Courtesy of Mike Dalbert www.treeline.ch ). 
 
These layers together provide a size- and charge-selective barrier (Brenner et al., 
1977). Hormonal, neural and vasoactive substances influence renal blood flow 
and glomerular filtration. Low molecular weight (LMW) molecules with radii 
< 20-25 Å (or less than ≈ 25 kDa) are relatively freely filtered, and those with 
radii >50-55 Å (or weights of  more than ≈ 70 kDa) are to a great extent excluded 
from filtration (D'Amico & Bazzi, 2003; Oliver et al., 1992; Maack et al., 1979). 
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Apart from size and charge, the sieving coefficient (glomerular permeability) of 
different substances, especially medium-sized ones, also depends on the 
flexibility and shape of circulating molecules (Lindstrom et al., 1997; Maack et 
al., 1979).  
The fraction of plasma that is filtrated depends on glomerular plasma flow, 
intraglomerular hydrostatic pressure, and ultrafiltration coefficient Kf (where Kf 
is the product of filtration barrier permeability and surface area) (Deen et al., 
1972). The filtrated plasma (ultrafiltrate, or primary urine) enters Bowman´s 
capsule, which constitutes the first part of the renal tubular system. The rate of 
filtration by the glomeruli, or the GFR, is defined as the amount of ultrafiltrate 
that forms in the nephrons per unit of time. The level of GFR in an individual 
person or animal with healthy kidneys is set by the metabolic rate (Singer, 2001). 
Bowman´s capsule opens up into the proximal tubules, where 66-75% of the 
ultrafiltrate is reabsorbed, including approximately 60% of filtered sodium, 
potassium and chloride, 70% of filtered calcium, and 80% of filtered phosphate 
and bicarbonate (Boron, 2006; Duarte & Watson, 1967; Malnic et al., 1964). 
Glucose and amino acids, such as cystine, ornithine, lysine and arginine are 
almost completely reabsorbed in the proximal tubular segment (Silbernagl, 
1988). Small filtered proteins such as albumin (most of which is retained from 
filtration, but filtered in small amounts in healthy individuals), are reabsorbed 
into proximal tubular cells by megalin-mediated pinocytosis (Vinge et al., 2010; 
Lazzara & Deen, 2007).  
In the remaining parts of the tubular system, further concentration of urine 
and necessary adjustment of acid/base-, mineral- and electrolyte-status occurs. 
The filtrate then enters the renal pelvis and the urethra for transport to the urinary 
bladder as urine. Blood that is not filtered in the glomerulus and instead enters 
the efferent arteriole flows through another, peritubular, capillary system. These 
capillaries provide oxygen and nutrition to the renal parenchyma, including the 
tubular system (Beeuwkes & Bonventre, 1975).  
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Fig 2. Normal glomerulus. Light microscopy image of a canine renal corpuscle (glomerulus) and 
the surrounding tubuli. Periodic acid-Schiff stain. (Courtesy of Fredrik Södersten). 
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Disease affecting the kidneys has traditionally been grouped in two main forms 
according to the clinical course; acute kidney injury (AKI) and CKD. Chronic 
kidney disease is often regarded a result of repeated, smaller insults to the kidney 
(Nenov et al., 2000). However, one major injury may also lead to development 
of CKD (Venkatachalam et al., 2010). Consequently, AKI may result in CKD, 
but is also a complication thereof, in that an individual with CKD may be 
predisposed to further injury, “acute-on-chronic disease” (Venkatachalam et al., 
2010). Recently, an even closer interrelation between AKI and CKD has been 
proposed in both human and veterinary medicine (Cowgill et al., 2016; Chawla 
& Kimmel, 2012). It has been suggested that mechanisms of pathogenesis may 
be shared between the two. If this is true, CKD may be thought upon as a slowly 
(or of variable pace) progressing acute, or ongoing, kidney injury (Cowgill et 
al., 2016). 
 
Fig 3. Diseased glomerulus. 
Light microscopy of a renal 
biopsy sample from a miniature 
poodle included in paper III. 
Morphological lesion 
(identified by use of electron 
microscopy): Focal segmental 
glomerulosclerosis. (Courtesy 
of the European Veterinary 
Renal Pathology Service). 
Periodic acid- Schiff stain. 
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Chronic kidney disease may be broadly divided into glomerular or 
tubulointerstitial disease. In glomerular disease, dysfunction of the filtration 
barrier is present (Fig 3). Thus, the hallmark of glomerular disease is renal 
protein loss (renal proteinuria). Glomerular damage may be categorised as 
immune-complex glomerulonephritis (ICGN) or non-ICGN (amyloidosis, focal 
segmental glomerulosclerosis) (Cianciolo et al., 2016). Multiple genetic 
abnormalities that result in glomerular dysfunction have also been described 
(Littman et al., 2013; Nowend et al., 2012; Davidson et al., 2007). 
Tubulointerstitial disease refers to a disease process present in any area of the 
kidney apart from the glomerulus and pelvis, and examples that occur in dogs 
are renal dysplasia and Fanconi syndrome (Hoppe & Karlstam, 2000; Bovee et 
al., 1978). Chronic tubulointerstitial fibrosis is also the final pathway of CKD 
irrespective of underlying pathology, and the degree of tubulointerstitial damage 
is the morphological feature that is most closely associated with GFR (Nath, 
1992; Schainuck et al., 1970).  
3.1 CKD aetiologies 
Many different underlying mechanisms of renal damage may lead to CKD. 
These include inflammatory, immune mediated, infectious, vascular, metabolic 
or neoplastic disease, toxicity, trauma, and genetic predisposition. The exact 
aetiology is often not known in dogs that are given a clinical diagnosis of kidney 
disease. 
3.2 Disease development 
During the clinical course of progressive CKD when nephrons are continuously 
lost, remaining nephrons undergo hypertrophy. Single nephron GFR increases 
(glomerular hyperfiltration) because of afferent (and to a lesser extent, efferent) 
arteriolar relaxation (Brown et al., 1990; Deen et al., 1974). These adaptive 
responses may initially be considered beneficial in maintaining global GFR, but 
over time, glomerular hypertrophy and hyperfiltration are thought to contribute 
to glomerulosclerosis and further nephron loss (Finco et al., 1999; Brown et al., 
1990; Brenner et al., 1982). At what level of decrease in nephron mass the 
inherent, self-perpetuating progression starts is not known. Approximately 31/32 
removal of renal mass in dogs results in moderate azotaemia (≈177-253 µmol/L) 
after allowing time for compensatory hypertrophy and hyperfiltration (Finco et 
al., 1999; Finco et al., 1994; White et al., 1991). This degree of azotaemia is 
common in dogs diagnosed clinically with CKD. Consequently, it has been 
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suggested that self-perpetuating disease may be present in many dogs at 
diagnosis (Finco et al., 1999).  
Variables associated with progression 
Several clinicopathological variables have been associated with progression in 
dogs and people (Fig 4). Proteinuria is probably the variable with most evidence 
of an association with progression in dogs as well as in cats and people (Zoja et 
al., 2015; Chakrabarti et al., 2012; Li et al., 2010; Syme et al., 2006; Jacob et 
al., 2005; Peterson et al., 1995), The exact role of proteinuria in the pathogenesis 
and progression of canine CKD is uncertain, but recent evidence in canine 
medicine suggests that proteinuria may be a cause of tubulointerstitial damage 
rather than only a consequence of glomerular or tubular dysfunction, as shown 
in people (Benali et al., 2013; Vilafranca et al., 1995; Eddy & Michael, 1988). 
Excess filtered protein results in increased proximal tubular cell pinocytosis of 
proteins, which in turn may result in cellular damage because of swelling and 
rupture of lysosomes and increased production of pro-inflammatory mediators 
(Benali et al., 2013; Vilafranca et al., 1995; Bertani et al., 1986). Proteinaceous 
casts may also obstruct tubuli and contribute to intrarenal damage.  
 
Fig 4. Simplified model of pathophysiological factors contributing to progression and accumulating 
fibrosis in chronic kidney disease. 
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The exact aetiology of CKD may influence rate of progression in dogs and 
people, as may superimposed clinical or subclinical AKI, “acute-on-chronic 
disease” (Venkatachalam et al., 2015; Polichnowski et al., 2014; Williams et al., 
1988). Other factors associated with rate of progression are systemic and 
glomerular hypertension (Lash et al., 2009; Finco, 2004; Jacob et al., 2003; 
Tozawa et al., 2003), intrarenal hypoxia (Tanaka et al., 2014; Mimura & 
Nangaku, 2010) and the mineral and bone disease associated with CKD, CKD-
MBD (Lippi et al., 2014; Natoli et al., 2013).  Recently, dehydration and osmotic 
stress were recognised as potential driving forces of progression in people with 
CKD (Gil et al., 2018; Clark et al., 2016). Reactive oxygen species generation, 
or “oxidative stress”, may play a central part in the pathogenesis of progression 
of CKD of both dogs and people, potentially involving several of the 
aforementioned factors (Kogika et al., 2015; Xu et al., 2015; Brown, 2008).  
Tissue fibrosis 
Parenchymal destruction and fibrosis is the final pathway in the pathogenesis 
and the common end-point of progressive CKD, regardless of aetiology. 
Fibrosis, which may affect all parts of the kidney, is called glomerulosclerosis 
when affecting the glomerular compartment, and tubulointerstitial fibrosis when 
affecting the tubulointerstitial compartment. Because of the intimate connections 
between these functional parts, disease in one compartment negatively affects 
the other. An example of this is the tubulointerstitial damage that may arise 
secondary to glomerular proteinuria (Lazzara & Deen, 2007).  
The division of renal fibrosis pathophysiology into four phases has been 
suggested, based on studies predominantly in rats and mice (Eddy, 2000). Recent 
studies have shown similar histopathologic patterns in canine progressive CKD 
(Benali et al., 2014; Aresu et al., 2011). The first phase, “cellular activation and 
injury”, is characterized by recruitment of inflammatory cells and appearance of 
myofibroblasts. In the second “fibrogenic signalling” phase, the number of 
myofibroblasts increase. During the third, “fibrogenic” phase, accumulation of 
ECM occur because of an imbalance between matrix synthesis and degradation. 
In the fourth, “renal destruction” phase, ECM accumulation and nephron 
destruction is seen. The start of the fourth phase was described as the point of 
irreversibility, because of permanent destruction of renal structural elements. 
These phases have been studied in animal models after injury at one point in 
time, but in spontaneous disease many or all of these phases may be observed 
histologically at the same time (Eddy, 2000).  
Synthesis, degradation and renal accumulation of ECM proteins and 
induction of proteases and other ECM-remodelling enzymes all contribute to 
development of renal interstitial fibrosis and disease progression (Eddy, 2014). 
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Renal tubular epithelial cells are thought to play a role in both the initial 
lymphocyte recruitment and in the fibrogenic phases as progenitors to the 
increasing population of myofibroblasts in the canine kidney (epithelial-to-
mesenchymal transition (Benali et al., 2014). The induction and proliferation of 
myofibroblasts is thought to represent a central event in the initiation and 
propagation of fibrosis in dogs and people (Benali et al., 2014; Genovese et al., 
2014).  
 
3.3 Prognosis 
The long-term prognosis for dogs with a diagnosis of CKD is often referred to 
as grave. However, the outcome is considerably variable between dogs, partly 
because of differences in progression rates and partly as a result of the definition 
of canine CKD. Some dogs that are given a diagnosis of CKD at an early stage, 
do not develop progressive CKD. Also, a CKD diagnosis can be based on 
persistent (>3 months) renal proteinuria, which may later resolve. Consequently, 
canine CKD, as currently defined in veterinary medicine, may be either static 
(non-progressive) or active (progressive). When the disease is progressive, most 
dogs proceed to end-stage disease and death, but rate of progression is variable 
both within and between individuals (Finco et al., 1999). It is difficult to predict 
the rate of progression in individual dogs. The fact that progression presumably 
is neither linear nor predictable is also recognised in human medicine (Onuigbo 
& Agbasi, 2014).  
3.4 Clinical signs  
Dogs with CKD may not show any clinical signs of disease. Because of the large 
reserve capacity of kidneys, clinical signs do not ensue until considerable loss 
of renal mass has occurred. Consequently, renal compromise is substantial at the 
time of diagnosis in many dogs. Clinical signs that may be present are PU/PD, 
weight loss, stunted growth, inappetence and vomiting, depending on degree of 
renal function loss.  
3.5 Systemic consequences 
When nephrons are lost and multiple renal functions decline, systemic 
consequences are inevitable. Some of the factors have been associated with CKD 
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progression, as mentioned above, and others (e.g. urinary tract infection, UTI) 
may be either a cause or a consequence of CKD.  
The cardiovascular system and the kidneys interact extensively in both health 
and disease. Haemodynamic stability (including circulating volume and 
vasomotor tone), is controlled by the kidneys and the cardiovascular system in 
concert and disease of one organ system may lead to disease of the other. In 
people, cardiovascular pathology is a significant cause of morbidity and 
mortality in CKD patients (Di Lullo et al., 2015; McCullough & Verrill, 2010). 
It has been shown in people that the age-specific risk of cardiovascular events 
was 17-fold higher in individuals with a low estimated GFR (eGFR; 
<15 ml/min/1.73 m2) compared to those with a higher eGFR (DuBose, 2007). 
The term “cardiorenal syndrome” is used in human medicine to describe the 
pathological interplay between the two organ systems (Braam et al., 2014; 
Brisco & Testani, 2014). Clinical importance of this interplay in canine patients 
remains unknown and the specific interactions may differ from those in humans, 
as well as between animal species. Therefore, the term cardiovascular renal axis 
disorders (CvRD) has been proposed for use in companion animal medicine 
(Pouchelon et al., 2015). Disease or dysfunction of the cardiovascular system 
secondary to kidney disease was further characterised as CvRDk. Direct 
evidence for the existence of CvRDk in dogs is scarce, but detrimental 
interactions between the kidney and the cardiovascular system have been 
documented. Examples are hyperkalaemia, anaemia, hypertension and hyper- or 
hypovolemia. In addition, decreased renal excretion of potentially toxic 
substances in individuals with kidney disease may negatively affect the 
cardiovascular system.  
Biomarkers may be used to evaluate cardiovascular compromise in dogs with 
CKD. Cardiac-specific troponin I (cTnI) is released into the circulation in 
response to myocyte injury, and amino-terminal pro-B-type natriuretic peptide 
(NT-proBNP) in response to myocardial wall stretch. This stretch may be caused 
by increased arterial blood pressure or increased circulating blood volume, 
leading to intracardiac pressure overload (Maeda et al., 1998). Higher serum and 
plasma concentrations of both cTnI and NT-pro-BNP have been documented in 
dogs with azotaemia, compared to healthy dogs (Raffan et al., 2009; Schmidt et 
al., 2009; Sharkey et al., 2009; Boswood et al., 2008; Porciello et al., 2008). If 
these high biomarker concentrations are indications of CvRDk or of 
accumulation due to decreased GFR in dogs, has not previously been studied. 
Circulating blood volume may decrease or increase, particularly in later stages 
of CKD, or if pronounced proteinuria and nephrotic syndrome are present 
(Klosterman et al., 2011).  Increased cTnI concentrations in people with CKD 
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have been documented, but the reason for cTnI leakage from myocardial cells is 
not known (Freda et al., 2002).  
    Anaemia is a common complication of canine CKD (Kogika et al., 2015). 
Relative deficiency of EPO, uraemia-induced erythrocyte membrane fragility, 
and gastro-intestinal blood loss have all been suggested to contribute to anaemia 
development (Crivellenti et al., 2017; Fiocchi et al., 2017). Weakness, lethargy 
and renal medullary hypoxia are possible clinical consequences.  
    Systemic hypertension occurs in canine CKD. The healthy canine kidney 
is capable of autoregulation through tubuloglomerular feedback and myogenic 
properties of vessel walls (Just et al., 1998; Herbaczynska-Cedro & Vane, 1973). 
This way, ideal intrarenal blood pressure is maintained throughout a wide range 
of renal perfusion pressures. In the diseased kidney however, autoregulation 
capability may decrease and increased systemic blood pressure may further 
damage the glomerulus and contribute to glomerular protein loss. 
 As renal function declines, the ability to excrete phosphate decreases. 
Adaptive change in concentration of fibroblast growth factor 23 (FGF-23) is 
necessary in order to maintain the concentration of phosphate within the 
reference interval. Increased FGF-23 and parathyroid hormone represent early 
indicators of CKD-MBD, or secondary renal hyperparathyroidism (Harjes et al., 
2017). Possible clinical consequences of CKD-MBD are osteodystrophy, 
metastatic tissue calcification and CKD progression (Shipov et al., 2018; Lippi 
et al., 2014; Olgaard et al., 1984). Additional systemic consequences of CKD 
include acid-base and electrolyte disturbances, inappetence, nausea, gastro-
interstinal pathology and urinary tract infection. 
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A clinical diagnosis of canine CKD requires documentation of decreased renal 
function, structural renal pathology, or both. There is also a temporal aspect to 
the diagnosis, in that any abnormalities detected must have persisted for a period 
of time, usually three months or more, as mentioned in section 1 (Polzin, 2017). 
This temporal aspect is assured either by documenting persistence of 
abnormalities for at least the time period specified, or by documenting 
abnormalities that are by definition chronic (pronounced fibrosis).  
Every clinical diagnostic evaluation starts with obtaining a case history and 
performing a physical examination. These crucial initial steps constitute the 
basis for determining pre-test probability of disease, unless the diagnosis is 
immediately obvious. Knowledge of the occurrence of different diseases in dog 
populations is clinically helpful, contributing value in the diagnostic thought 
process.  
4.1 Epidemiology of kidney disease in dogs  
Incidence- or mortality rates of CKD in dogs have not previously been reported. 
Incidence relates to new occurrences of disease over a period of time (Fig 5), 
and are usually expressed as a proportion (cumulative incidence) or a rate. The 
incidence rate (IR) refers to the number of new cases that develop per unit of 
time. Similarly, mortality rate (MR) refers to the number of deaths that occur per 
unit of time. Calculation of incidence (and mortality) rates requires knowledge 
of the population at risk. This information is often not available, and therefore, 
prevalence constitutes the epidemiological term most commonly estimated in 
canine medicine.  
Prevalence refers to the proportion of individuals that are affected by disease 
at any point in time, in a defined group of individuals (Fig 5). Prevalence 
calculations are often performed in “convenience” populations, such as the total 
4 Diagnosis of CKD   
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number of dogs that visited one or more veterinary medical institutions over a 
specified duration of time. As a result, external validity of the results may be 
limited (referral bias) (Bartlett et al., 2010). 
Technical developments have led to an increasing number of information 
registers and databases where information is gathered, which is potentially 
useful for epidemiological studies. If the information in a database was not 
collected with the explicit purpose of research, it is referred to as secondary 
rather than primary (Emanuelson & Egenvall, 2014). In secondary databases, 
sample size can be considerable, representativeness of the population high and 
risk of bias, such as non-response or recall bias, low (Roos L L, 1990). The main 
limitation is suboptimal data resolution. Validation of the chosen data source for 
the intended use should be performed (Emanuelson & Egenvall, 2014). 
 
Fig 5. Schematic illustration of epidemiological concepts. Prevalence – proportion of affected 
individuals at one point in time. Incidence - new occurrences of disease over a specified period of 
time. Prevalence decreases when individuals regain health, or when they die, and thereby leave the 
population. Treatment of disease may delay death (increase prevalence) or facilitate cure (decrease 
prevalence). Disease chronicity is another factor that influences prevalence, because the longer the 
time that an individual is affected, the more individuals will have the disease at one point in time 
(increased prevalence). Thus, prevalence is useful for determining the burden of a disease on a 
population, while incidence provides useful information regarding risk of contracting disease and 
changes in disease occurrence over time. 
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4.2 Assessment of kidney structure (morphology) 
 
Structural damage to the kidneys may be assessed macroscopically at surgery, 
or at post mortem examination. Different diagnostic imaging modalities; 
radiography, ultrasound, computed tomography (CT) and magnetic resonance 
imaging provide less invasive options for macroscopic evaluation of renal 
morphology in clinical patients. With the use of ultrasound, the size, shape, and 
parenchymal architecture of the kidneys may be assessed (Fig 6). Echogenicity 
of the canine renal cortex is similar to that of the liver and slightly less echogenic 
than that of the spleen. The medulla is less echogenic than the cortex and the 
cortico-medullary border is normally readily identified.  
Diagnostic imaging modalities are effective in diagnosing focal morphologic 
abnormalities such as mass lesions, fluid accumulation, renal cysts or agenesis, 
but for definitive diagnosis of diffuse parenchymal disease, histopathology is 
needed. This may be performed either by obtaining renal biopsies from a living 
dog, or as part of a post-mortem examination. Renal biopsy should only be 
performed when results are likely to be of value in case management, and when 
no contraindications, such as uncontrolled hypertension, coagulopathy or severe 
azotaemia, are present.  
Fig 6. Image acquired 
by renal ultrasound, 
showing an example of 
structural abnormality; 
multiple cysts in the 
left kidney (arrows) in 
one of the dogs with 
polycystic kidney 
disease, included in 
studies II-IV.  
(Courtesy of Chiara 
Mattei). 
4.3 Assessment of global function (GFR) 
Measurement of GFR is generally considered the most sensitive index of 
functional renal mass and the best indicator of global renal function. The GFR 
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may be calculated by different methodologies. The golden standard method in 
human medicine is urinary clearance of inulin, but this method is not practical 
in the clinical setting (Von Hendy-Willson & Pressler, 2011). Plasma clearance 
studies negate the need for timed urine collections and, instead, rely on timed 
blood collections (Heiene & Moe, 1998). Limited sampling methods for clinical 
use have been proposed for both dogs and cats (Finch et al., 2011; Heiene & 
Moe, 1999). 
 With image-based techniques, renal uptake of a filtered marker can be 
measured. Two examples of imaging techniques that have been validated for 
GFR measurement in dogs are scintigraphy and dynamic computer tomography 
(Chang et al., 2011; Krawiec et al., 1988). Contrast-enhanced computer 
tomography has been described to underestimate global GFR compared to both 
scintigraphy and clearance of iohexol in healthy dogs (O'Dell-Anderson et al., 
2006). 
Results from any GFR-assessment technique represents the GFR 
accomplished by the kidney(s) at the very time of measurement (in relation to 
the normalisation variable), not the GFR that “could” be obtained in an optimal 
situation, which is sometimes mistakenly assumed. Any measured value is the 
combined result of pre-renal, renal and post-renal factors affecting GFR. 
Hypotension may decrease GFR because of decreased hydrostatic pressure in 
the glomerular capillary tuft, and urinary obstruction increases hydrostatic 
pressure in Bowman´s capsule, thus decreasing GFR. Another important clinical 
feature is the chronicity of any GFR decrease. The obtained GFR value may 
represent a chronic, successive decrease, or an acute decrease or a combination 
of both (Cowgill et al., 2016; Grauer, 1998). These aspects are important in the 
clinical assessment of an individual case. 
Also, importantly, GFR in a clinically stable dog with progressive CKD at 
any point in time represents a balance between nephron hypertrophy/ 
hyperfiltration and nephron destruction. Thus, if renal function is perceived as 
stable in a dog over time, this may represent truly stable function, but it may also 
represent a balance between nephrons that are destructed and nephrons that are 
over-working in order to maintain global function (Finco et al., 1999). 
Measurement of GFR conveys no information regarding which intrarenal 
processes that are occurring at a specific point in time. Rather, the net effect of 
these processes is measured. 
In clinical practice, GFR is most often estimated by measuring concentrations 
of circulating indirect biomarkers, such as creatinine, but techniques for GFR 
measurement, for example clearance studies or scintigraphy, are also sometimes 
used. 
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4.3.1 Scintigraphy  
With renal scintigraphy, a two-dimensional picture of the urinary tract is 
produced, in that the uptake of an intravenously injected radiopharmaceutical 
(Technetium-99m-dietylene-triaminepentaacetic acid, 99mTc-DTPA) over time 
is detected by a gamma camera that counts radioactive emissions. The 
pharmaceutical (DTPA) meets the criteria stipulated for a good marker of GFR, 
and its uptake by filtration in the kidney, as a fraction of the injected activity of 
99mTc-DTPA, is directly related to GFR (Gates, 1982). Several techniques exist 
for measurement of GFR following scintigraphy. Two examples are the integral 
(or Gates´) method and the plasma volume method (Kampa et al., 2007; Gates, 
1982). Calculation of GFR is performed for each kidney separately. Renal 
scintigraphy with 99mTc-DTPA has been evaluated and found useful for GFR-
measurement in dogs (Krawiec et al., 1988).  
In order to compare GFR between individuals, it must be normalised to some 
measurement related to body size. In human medicine, GFR is often normalised 
to body surface area (BSA). The use of BSA as a normalising factor has been 
questioned in veterinary medicine, especially for drug dosing (Price & Frazier, 
1998). In dogs, GFR is usually normalised to body weight (BW, integral method) 
although methods of normalisation to plasma volume also have been 
recommended (Westgren et al., 2014; Kampa et al., 2007). From the 
physiological standpoint, because GFR changes in accordance with volaemic 
status of the animal (Chew & Gieg, 2006), normalisation of GFR to plasma 
volume is more reasonable than BW. Receptors for detection of volume status 
are present in the intravascular space and not in the interstitial fluid space, and 
therefore plasma volume is conceptually superior for normalisation of GFR 
compared to the extra-cellular fluid volume (Peters et al., 1994). Reference 
intervals for GFR in dogs remain poorly defined and vary with methodology, 
normalisation method and individual characteristics of the animal (Von Hendy-
Willson & Pressler, 2011). Bodyweight has been shown to be associated with 
GFR measured by plasma clearance of iohexol in a study of 118 dogs (Bexfield 
et al., 2008). Therefore, slightly different reference intervals were proposed for 
the different BW quartiles (2-12, 13-25, 26-31 and 32-70 kg, respectively).  
4.3.2 Circulating biomarkers  
For a long time, creatinine has been the circulating biomarker of choice for a 
quick and simple, relatively non-invasive, assessment of GFR. Creatinine 
concentration is also used for staging of CKD (section 4.3.3). Other markers of 
decreased GFR, for example cystatin C and symmetric dimethyl arginine 
(SDMA) have been studied. Recently, SDMA was made commercially available 
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and is now extensively used for evaluation of renal function in dogs. The value 
of adding other circulating markers to creatinine in the clinical work-up of dogs 
with suspected CKD is not known. 
Creatinine 
Creatinine in the circulation originates mainly from degradation of creatine and 
creatine phosphate in muscle tissue, but a small part may originate from 
alimentary supply (Harris et al., 1997).  Creatinine is released into the circulation 
at a stable rate proportional to muscle mass, cleared by glomerular filtration and 
not reabsorbed. Urinary elimination of creatinine is relatively constant over time 
in an individual, but may differ greatly between individuals (Jergens et al., 1987; 
Barsanti & Finco, 1979). Minimal tubular secretion occurs in male dogs 
(O'Connell et al., 1962) but this is of little significance (Watson et al., 2002; 
Labato & Ross, 1991). Therefore, creatinine possesses many of the properties of 
an optimal biomarker of GFR.  
Methods of creatinine concentration measurement include the Jaffe reaction 
and enzymatic methods. Enzymatic methods are preferred because of the 
interaction of non-creatinine chromogens with the Jaffe reaction (Delanghe & 
Speeckaert, 2011).  Unfortunately, no international standardisation of creatinine 
analysis has been performed despite differences in assay performance (Ulleberg 
et al., 2011; Braun et al., 2008). In addition, reference ranges differed 
extensively between laboratories (Ulleberg et al., 2011). Creatinine 
concentration is generally higher in large breeds (Finch & Heiene, 2017; 
Middleton et al., 2017; Misbach et al., 2014; Medaille et al., 2004; van den Brom 
& Biewenga, 1981), and different reference intervals for different BW quartiles 
have been suggested. Creatinine concentration is higher in greyhounds 
(sighthounds) than in many other breeds (Dunlop et al., 2011; Zaldivar-Lopez et 
al., 2011; Feeman et al., 2003). Published data concerning the effect of age on 
creatinine concentration are somewhat inconsistent but it seems that creatinine 
concentration decreases in the first days after birth, then remains stable for two 
months, after which it increases until approximately one year of age (Wolford et 
al., 1988). Thereafter, it remains comparably stable until a high age (Fukuda et 
al., 1989). In one study, there was no difference between creatinine 
concentrations in young compared to old Beagle dogs (Vajdovich et al., 1997). 
Symmetric dimethyl-arginine 
A new potential circulating biomarker of GFR is SDMA. It is derived from 
intracellular protein metabolism and mainly cleared by glomerular filtration 
(McDermott, 1976; Kakimoto & Akazawa, 1970). In human medicine, SDMA 
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concentration is not widely used clinically as a marker of GFR, but its diagnostic 
value has recently been studied (El-Khoury et al., 2016; Kielstein et al., 2011; 
Tutarel et al., 2011). A liquid chromatography-mass spectrometry assay of 
SDMA has been validated (Nabity et al., 2015). Other assays for SDMA 
measurement in dogs are currently available and extensively promoted on the 
veterinary market. There is, however, very limited information available about 
the diagnostic performance of SDMA concentration in plasma or serum as a 
marker of GFR in dogs (Nabity et al., 2015). Age, sex and BW have been 
described not to influence SDMA concentrations in dogs (Moesgaard et al., 
2007; Pedersen et al., 2006). The SDMA concentration has been shown to be 
stable in samples stored for seven and 14 days at 20° and 4°, respectively, and 
after three freeze-thaw cycles (Nabity et al., 2015).  
Cystatin C 
Cystatin C, a low-molecular-weight (13 kDa) cysteine protease, is produced at a 
stable rate by all nucleated cells and cleared by glomerular filtration (Jacobsson 
et al., 1995; Abrahamson et al., 1990). Neither age nor BW seem to significantly 
affect circulating cystatin C concentration in people or in dogs (Miyagawa et al., 
2009; Wehner et al., 2008; Finney et al., 2000; Norlund et al., 1997). In one 
study, cystatin C concentrations were marginally higher in young and old dogs 
than in mature adults, but the difference was not large enough to warrant 
different reference intervals in different age groups (Braun et al., 2002). 
Cystatin C is routinely used in equations for calculation of eGFR in people, 
either alone or together with creatinine (Grubb et al., 2014; Larsson et al., 2004). 
In dogs, cystatin C concentration in serum or plasma has been evaluated as a 
marker of GFR using different analytical methods and study designs, and this 
biomarker is considered potentially useful (Miyagawa et al., 2009; Wehner et 
al., 2008; Almy et al., 2002).  Exogenous corticosteroid administration can 
increase cystatin C concentrations in dogs, in contrast to endogenous 
overproduction in hyperadrenocorticism (Muñoz et al., 2017; Marynissen et al., 
2016). Hyper- and hypothyroidism has been shown to affect cystatin C 
concentrations, at least in cats and people (Ghys et al., 2016; Jayagopal et al., 
2003).  
Diagnostic test properties relevant to biomarkers of GFR 
Many aspects of biomarkers of disease need consideration. The most commonly 
communicated properties of a diagnostic test are sensitivity and specificity. 
When results of a diagnostic test are interpreted, however, sensitivity and 
specificity have no direct diagnostic meaning. Predictive values are more useful 
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in this respect, but unfortunately differ considerably between individuals with 
different pre-test probabilities, and thus cannot be used as fixed properties of a 
certain test (Gallagher, 2003).  
In contrast, a diagnostic test property that is stable (not critically dependent 
on disease probability), and therefore may be conveniently applied across 
individuals and populations, is the likelihood ratio (LR) (Dujardin et al., 1994). 
Calculated from sensitivity and specificity, it summarizes information from both 
terms and provide the discriminatory power of the test. These ratios are 
presented as positive (LR+) and negative (LR-) ratios, where LR- is a number 
between 0 and 1, and LR+ a number ≥ 1. Pre-test probability of disease is 
multiplied with the LR to provide a post-test probability of disease. Diagnostic 
tests with LR- below 0.1 or LR+ >10 modify the pre-test probability in a highly 
useful way (Gallagher, 1998).  
For continuous tests like the indirect biomarkers of GFR, LRs may also be 
defined for multiple intervals of the test result. With the use of such interval LRs, 
more information from a test result is gained, compared to when continuous 
results are dichotomised as positive/high or negative/normal.  
In veterinary medicine, cross-sectionally derived, population-based, 
reference intervals are used in the interpretation of diagnostic test results. The 
total variation between results from a group of individuals (used to create a 
population-based reference interval) consists of the sum of pre-analytical, 
analytical, inter-individual (CVg) and intra-individual (CVi) variation. The CVg 
contributes with a large part of the width of population based reference intervals 
for some variables. An example of such a variable (with CVg >> CVi, or a high 
individuality) is creatinine. The concentration (of for example creatinine) in an 
individual over time may reside in the middle, towards the upper or lower 
reference limits, or even outside a population-based reference interval (Fraser, 
2004). This markedly affects overall diagnostic performance of the biomarker. 
Assigning different reference intervals to relevant sub-groups, for example breed 
(stratification), may improve utility of such a test. Alternatively, a longitudinally 
derived reference change value (RCV), determined based on the analytical and 
biological variation of a variable, may be used (Walton, 2012). This way, a 
significant change (possibly indicating pathology) between two consecutive 
measurements can be detected even if both results are within a broad population 
based reference interval. 
 
39 
 
4.3.3 Staging of canine CKD 
Staging of CKD provides an opportunity for a comparable description of clinical 
cases and makes the development of specific recommendations regarding 
diagnostic tests and treatment options for patients in different stages of disease 
possible. The international renal interest society (IRIS) has developed a staging 
system for CKD in dogs (IRIS, 2016). It is based on “stable” (i.e. in steady state) 
fasting serum creatinine concentration, in order to make staging possible in 
virtually every clinical environment. Staging can only be done once a definitive 
diagnosis of CKD has been established. 
Stage 1 dogs are those with a stable creatinine concentration <125 µmol/L. 
Stage 2 includes dogs with a creatinine concentration between 125-180 µmol/L, 
stage 3 those between 181-440 µmol/L and stage 4 dogs those with a creatinine 
concentration >440 µmol/L (IRIS, 2016). Substaging of CKD is performed by 
including results from blood pressure measurement and persistent renal 
proteinuria assessment. The lack of standardisation of creatinine assays and the 
variation in creatinine concentration between dogs of different bodyweights and 
breeds noted above, as well as blood pressure equipment and procedure 
variations, might leave staging of canine CKD a somewhat imprecise activity. 
4.4 Urine analyses 
4.4.1 Routine urine analyses 
Urine has long been used for diagnostic purposes in the medical profession. 
Already in the 17th century, “piss-prophets” diagnosed all sorts of diseases by 
looking at the colour of, and sometimes tasting, urine from their patients. Urine 
represents a unique diagnostic fluid because it may be obtained non-invasively 
in large amounts.  Also, it represents a fluid sample produced by and acquired 
from the kidney, and as such is invaluable for renal diagnostic procedures. 
Despite this, urine analysis is sometimes underutilised by veterinarians. Urine 
may be collected by spontaneous voiding, catheterization or cystocentesis. 
Results of any diagnostic tests are interpreted in light of collection method as 
well as of storage time and temperature, if urine analysis is delayed. Collection 
of urine is preferably performed before administration of fluids or other types of 
medication. Initially, colour and appearance of urine are subjectively assessed, 
thereafter routine analyses are performed. These usually consist of dipstick 
analysis, urine specific gravity (USG) and sediment examination. 
If pathological proteinuria is suspected, quantification may be performed by 
determining the urine protein-to-creatinine ratio (UPC). Values of UPC from 
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random voided urine samples from dogs are correlated with total 24-hour protein 
excretion (Center et al., 1985; Grauer et al., 1985). International reference 
intervals and treatment thresholds exist and are in use, but presently, there is no 
international standardisation of UPC measurements. Pathologically high 
amounts of protein in the urine may be characterized as pre-renal, renal, or post-
renal. Renal proteinuria may be glomerular (filtration barrier leakage) or tubular 
(tubular cell dysfunction), or both. If proteinuria is renal and persistent 
(>3 months), CKD is present according to the current CKD definition. 
Biological variation of UPC is of clinical importance and should be taken into 
account both in diagnosis and in monitoring outcome of treatment (Nabity et al., 
2007).  
4.4.2 Urinary proteomics 
As noted in section 4.3, the kidneys possess a large functional reserve capacity 
and can compensate for large decreases in renal functional mass. Thus, a 
reduction in GFR does not occur until the compensatory adaptation of the 
kidneys fails. Therefore, even GFR measured with clearance studies or 
scintigraphy is a comparably insensitive indicator of decreasing renal function 
in CKD. Detection of the fibrotic process itself could possibly provide an earlier 
opportunity for diagnosis. Currently, the only way of definitively diagnosing 
interstitial fibrosis clinically is by renal biopsy. This procedure is costly, invasive 
and not without risk. The development of non-invasive, fibrosis-specific 
biomarkers, reflecting morphological tissue change at an early stage of CKD, 
could be a major breakthrough for earlier and more specific diagnosis of canine 
CKD. 
With the use of proteomics, multiple urinary proteins and peptides can be 
identified in a non-invasive manner. The urinary proteome, although less 
complex than that of plasma, contains thousands of proteins and peptides 
(Kentsis et al., 2009; Coon et al., 2008). Urine as a source of proteomic 
biomarkers is favourable since it contains a lower dynamic range of analytes 
compared to plasma. The urinary proteome is also thought to be highly stable 
because of minimal to no ongoing proteolysis in contrast to the situation in 
plasma (Mischak et al., 2010b).  
Proteins and peptides from the urinary tract are either secreted from tubular 
cells or originate from epithelial cells shed from any part of the urinary tract 
(including urethra and the genital tract if spontaneously voided urine is used). 
About 70% of the human proteome in health originated from the urinary tract 
itself in one study (Pieper et al., 2004). 
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Low molecular weight proteins and peptides in urine are either freely filtered 
through glomeruli from the blood, or they may originate from the urinary tract 
itself. Accumulated data indicate that approximately 80% of urinary peptides 
originate from the kidney (Krochmal et al., 2018). Many of the sequenced 
urinary peptides represent fragments of collagen. 
Diagnostic use of urinary proteomics-based classifying models represents a 
novel strategy that may substantially contribute to clinical management of CKD, 
particularly given the non-invasiveness of urine collection and the stability of 
the urinary proteome (Mischak et al., 2010a).  
Capillary electrophoresis coupled to mass spectometry 
Urinary proteome analysis by capillary electrophoresis coupled to mass 
spectrometry (CE-MS) enables robust and reproducible analysis of LMW 
proteins and peptides in people. The method provides fast (<1 hour) separation 
with high resolution at a low cost (Hernandez-Borges et al., 2004; Neususs et 
al., 2002). The CE-MS technology does not include tryptic digestion of urinary 
proteins, and therefore allows analysis of naturally occurring peptides. This 
subfield of proteomics is called peptidomics.  The CE-MS urinary peptidome 
analysis requires depletion of proteins with a molecular weight >20 kDa because 
larger proteins will clog the capillary. Hence, with the CE-MS approach, whole 
proteins cannot be assessed. Peptides that are bound to proteins are also removed 
in this step and therefore not assessed. There are, however, several advantages 
of focusing on peptides instead of proteins. The stability of the urinary 
peptidome is significantly higher than that of the urinary proteome, (Good et al., 
2010) (Good et al., 2010) probably because peptides are in themselves 
degradation products (Klein et al., 2016; Theodorescu et al., 2006). The human 
urinary peptidome is stable for three days at 4°C, several years at -20°C and after 
repeated freeze-thaw cycles (Mischak et al., 2013). Analysis of the urinary 
peptide content has also shown a higher reproducibility than proteomics 
analyses, presumably because in peptidomics analyses, mass spectrometry can 
be performed without tryptic digestion (Mischak et al., 2013).  
Using CE-MS, a classifying model consisting of 273 urinary peptide 
biomarkers has been developed and subsequently validated in a separate cohort 
of people (Good et al., 2010). This model, called CKD273, was shown to 
differentiate healthy individuals from those with CKD, irrespective of 
underlying aetiology. . The diagnostic potential of the CKD273-model has been 
confirmed in further, cross-sectional and prospective, studies (Roscioni et al., 
2013; Zurbig et al., 2012; Alkhalaf et al., 2010). The CKD273-model is 
currently applied for patient stratification in a multicentric randomised clinical 
trial, the PRIORITY trial (Pontillo & Mischak, 2017). The aim of this trial is to 
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investigate the potential benefit of early detection (by the CKD273-model), and 
spironolactone treatment, of human diabetic nephropathy.  
For diagnostic purposes, only peptide physiochemical properties (such as 
molecular mass and migration time) are necessary. Identification of 
differentially expressed, naturally occurring, peptides may, however, facilitate 
further pathophysiological insight. Over the last decade, urinary peptidomics has 
provided new information regarding human renal pathophysiological 
mechanisms. Naturally occurring urinary peptides, such as those identified with 
CE-MS, result from proteolytic activity in the body. Changes in extracellular 
protease activity may be responsible for changes in the urinary peptidome, which 
in turn may reflect presence (or progression) of a specific disease (Candiano et 
al., 2006).  
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The general aim was to increase knowledge regarding pathophysiologic 
mechanisms and early diagnosis of canine CKD, by identifying dogs with 
increased risk of disease and by exploring the use of various biomarkers in blood 
and urine. 
 
The specific aims were as follows: 
 
 To use data from a large insurance company database to estimate 
morbidity and mortality related to kidney disease in a Swedish population 
of insured dogs. 
 
 To investigate possible associations between plasma concentrations of 
cTnI and NT-proBNP, respectively, and patient characteristics, GFR, 
PVF/kg, SBP, selected hematologic and biochemical variables and 
echocardiographic measurements in dogs with stable CKD and in healthy 
dogs. 
 
 To compare the overall diagnostic accuracy for SDMA and cystatin C 
compared to creatinine, for detection of decreased GFR in clinically stable 
dogs with a diagnosis of, or a strong suspicion of, CKD. Also, to evaluate 
if combining SDMA, cystatin C, or both, with creatinine increases 
diagnostic value compared to the use of creatinine alone. 
 
 To evaluate if CE-MS-based urinary peptidome analysis can discriminate 
healthy dogs from dogs with CKD by constructing classifying models and 
validate them in a separate group of dogs. Also, to identify peptides 
included in the discriminating models. 
5 Aims of the thesis  
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6.1 Study populations and study design 
6.1.1 Insurance database (paper I) 
In paper I, data from a large Swedish insurance company was used to estimate 
kidney-related morbidity and mortality in Swedish insured dogs. The 
information in this database was previously validated against practice records 
(Egenvall et al., 1998). We used data on all dogs in the Agria Animal Insurance 
database over a 12 year period (1995 through 2006) to investigate the incidence 
of kidney-related disease (KD) in Swedish insured dogs. The exact time each 
dog was insured was calculated from the day they were insured until either a 
diagnosis of KD, death, withdrawal from insurance, or the end of the study 
period. The common denominator in all calculations was “dog year at risk” 
(DYAR). One DYAR equals one year of insurance participation for one dog. As 
an example, if a dog was insured on January 1st, 1997 and died on July 1st, 2004, 
the contribution of this dog to the study was 7.5 DYAR. The large size of the 
study population also made stratifications according to breed, sex and age 
possible. 
Calculations of incidence and mortality differences by breed were, however, 
restricted to breeds that contributed with more than a total of 10.000 DYAR, in 
an attempt to reduce bias. Incidence was calculated from data in the veterinary 
care insurance database and mortality was calculated from data in the life 
insurance database. The life insurance database contains data from dogs up to 10 
years of age only, and consequently no information on mortality of KD after 10 
years of age could be obtained. It was not possible to distinguish acute from 
chronic KD in this data. Consequently, results include both forms of disease. 
6 Comments on materials and methods 
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6.1.2 Prospectively recruited dogs (papers II-IV) 
Dogs with a diagnosis, or a strong suspicion, of CKD and healthy dogs were 
prospectively included at the University Animal Hospital in Uppsala between 
February 2012 and November 2016. Uppsala ethical committee approved the 
study and informed consent was collected from owners of all dogs included in 
the studies. The days of study inclusion of dogs were scheduled weeks ahead, in 
order to minimise any influence of for example acute-on-chronic disease that 
may be present when dogs are presented at the hospital. That way, we aimed to 
assure that GFR and other measured variables would reflect everyday 
homeostatic balance without influence of possible acute events. Owners were 
instructed to withhold food for 12 h before examinations. On the day of 
inclusion, a case history was obtained and every dog underwent a physical 
examination, repeated blood pressure measurements, urinary tract ultrasound, 
echocardiography and scintigraphy (Fig 7). Collection of blood and urine 
samples was performed, both for immediate analysis and for storage (-70°) until 
batch analysis. Dog-owners were present during all examinations, to keep dogs 
comfortable and calm. No dog was sedated. 
In addition to urine samples from the 105 dogs included according to study 
protocol, urine from six healthy research beagles were also used in the 
peptidomics analyses of paper IV. These beagles were considered healthy due to 
a healthy appearance and according to results of blood and urine routine 
analyses. Renal histopathology by light microscopy was also performed and 
considered normal, in all six beagles.  
Because of our attempt to include dogs in all stages of CKD, including those 
with mild, subclinical disease (stage 1), 14 of the included dogs with a suspicion 
of CKD, because of for example unexplained chronic PU/PD, could not be given 
a conclusive CKD diagnosis according to the current CKD definition. These 
dogs were classified as “inconclusive”. All included dogs were free of other 
significant systemic or organ-related disease. The reason for including 
inconclusive dogs in paper III was that 1) association of biomarkers with GFR 
was of interest irrespective of a CKD diagnosis, 2) a population with a suspicion 
of kidney disease is more closely representative of the clinical population in 
which the tests evaluated in the study are to be used, than is a population with a 
diagnosis of CKD and 3) avoidance of a case control scenario is important in 
diagnostic studies. Similar to clinical trials, diagnostic test accuracy studies are 
at risk for systemic biases (Whiting et al., 2013). There is evidence for effects 
on study validity of spectrum bias (case-control design) and partial or differential 
verification bias (using different reference tests, or a reference test that includes 
the index test), among others.  
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Fig 7. Flow-chart of included dogs in the PhD-project. 
 
In the urinary peptidomics study (paper IV), no inconclusive dogs were used for 
model construction or validation, but three inconclusive dogs were included as 
examples of clinical patients for which a peptidomics analysis may be 
informative. Fifteen dogs with CKD and 15 healthy dogs comprised the training 
set (peptidome model construction). Twenty separate dogs (10 with CKD and 
10 healthy dogs) comprised the independent validation set. Samples from dogs 
in the validation group (10+10 dogs) and from the three inconclusive dogs, were 
sent without identification and thus blinded to the researchers performing 
CE-MS analysis and the model validation process. Dogs with a confirmed 
diagnosis of CKD were staged according to the IRIS staging system described 
in section 4.3.3. 
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6.2 Examination procedures (papers II-IV) 
6.2.1 Blood pressure measurement  
Repeated systolic blood pressure (SBP) measurements were performed by high 
definition oscillometry (HDO) after 5-10 minutes of acclimatisation to the 
examination room. Dogs were held in standing position and minimally 
restrained. The cuff was applied at the tail-base in all dogs but one (which had 
no tail). In that dog, a front leg was used. At least 5-8 measurements were 
performed, and the mean of five SBP values with a variation of maximally ≈ 
20% was calculated and used in statistical analyses (papers II-III).  
6.2.2 Urinary tract ultrasonography 
Ultrasonography of the entire urinary tract was performed in dorsal recumbency, 
according to a pre-specified protocol. Examinations were performed by 
experienced radiographers at the diagnostic imaging clinic of the University 
Animal Hospital. At the end of each examination, if possible, 10-40 ml of urine 
was obtained by cystocentesis. 
6.2.3 Echocardiography 
Echocardiographic examinations were performed in order to exclude primary 
heart disease and to assess intracardiac volume status. Dogs were examined in 
right and then left lateral recumbency by experienced ultrasonographers and 
standard views were obtained. Left atrial and ventricular measurements were 
made on three consecutive cardiac cycles, and the mean value from each dog 
was used in the statistical analysis. The echocardiographic unit used was iE33, 
Philips Ultrasound, Bothell, USA. 
6.2.4 Sampling of blood and urine 
Blood was collected by venipuncture into two and four ml tubes containing 
EDTA, or with no additive, and transferred to the University Animal Hospital 
laboratory for immediate routine analyses (CBC and biochemistry panel). 
Remaining serum and EDTA plasma was frozen in aliquots at -20°C for a 
maximum of 24 h, and thereafter transferred to storage at -70°C. Urine was 
collected by cystocentesis at the time of abdominal ultrasonography for most 
dogs. If cystocentesis was not possible, fresh voided urine was collected. After 
allocation of urine for immediate examination at the University Animal Hospital 
laboratory (dipstick, USG, UPC, sediment examination and urine culture), 
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remaining urine was aliquoted into plastic cryo tubes and stored at -70° C. Urine 
from the six research beagles was snap frozen at the time of sampling, and 
thereafter stored at -70° until batch analysis (paper IV). 
6.2.5 Assessment of glomerular filtration rate  
The scintigraphic examination was performed with dogs in lateral recumbency 
(Fig 8), as previously described (Westgren et al., 2014; Kampa et al., 2007; 
Kampa et al., 2002). To obtain a dorsal view including kidneys and heart, the 
gamma camera was positioned vertically. Over six minutes, a dynamic 
acquisition was recorded at one frame per 10 seconds. Immediately after starting 
acquisition, a bolus of 70 mBq 99mTc-DTPA followed by a four ml saline flush 
was injected intravenously. In order to facilitate measurement of the distance 
between kidneys and gamma-camera, the camera was thereafter moved to a 
horizontal position above the dog, and a 30 second static lateral image was 
acquired. By subtracting pre- from post-injection syringe and catheter counts and 
correcting for radioactive decay, net injected radioactive counts were calculated. 
Commercial nuclear medicine software was used to calculate individual kidney 
GFR with both the integral method, in which GFR is normalised to BW, and the 
plasma volume method, in which GFR is normalised to plasma volume (Kampa 
et al., 2007). The pre-defined cut-off value for decreased GFR with the plasma 
volume method, which was used in statistical calculations, was 30.8 ml/min/L 
(Kampa et al., 2007). 
 
Fig 8. Positioning of a dog during 
scintigraphic examination. The 
gamma-camera is positioned 
vertically, obtaining a six-minute 
dynamic acquisition. (Courtesy of 
Ina Larsson). 
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6.3 Analyses 
6.3.1 Circulating biomarkers (papers II-IV) 
N-terminal pro-B-type natriuretic peptide (paper II) 
Frozen EDTA plasma was sent to Idexx Laboratories, Germany, for duplicate 
batch analysis of N-terminal pro B-type natriuretic peptide (NT-proBNP) with a 
commercially available canine ELISA (CardioPet proBNP, product number 
2665, IDEXX Laboratories, USA). The lower limit of detection was 250 pmol/L. 
Cardiac troponin I (paper II) 
Frozen EDTA plasma was sent to the Department of Clinical Chemistry, Skene 
Hospital, Sweden. Batch-analysis of cardiac-specific Troponin I (cTnI) 
concentration in duplicate was performed using a high-sensitivity assay, Access 
AccucTnI+3 Troponin I assay, Beckman Coulter, USA. This assay was 
previously validated for use in dogs (Oyama & Solter, 2004). The lower limit of 
detection was 0.01 µg/L.  
Creatinine (papers II-IV) 
Serum concentration of creatinine was measured at the clinical chemistry 
laboratory at the University Animal Hospital in Uppsala, on the day of inclusion 
as part of the biochemistry analysis panel, according to study protocol. An 
enzymatic method was used, analysed on the Architect c4000 (Abbott 
Diagnostics) analyser. The pre-defined cut-off of creatinine for diagnosis of 
decreased GFR was 115 µmol/L. 
Symmetric dimethyl-arginine (paper III) 
Frozen serum was transported to IDEXX Laboratories for batch analysis of 
SDMA by the method offered commercially to companion animal clinics 
(enzyme immunoassay). Duplicate analysis was, for unknown reasons, not 
performed as requested. The pre-defined cut-off of SDMA for diagnosis of 
decreased GFR was 14 µg/L. 
Cystatin C (paper III) 
Frozen serum was transported to the Department of Clinical Chemistry, Uppsala 
Academic Hospital, for batch analysis of cystatin C concentration in duplicate. 
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A particle-enhanced immuno-turbidimetric (PETIA) assay (Gentian, Moss, 
Norway) was analysed using Architect c8200 (Abbott, USA). This assay had 
been previously validated for use in dogs (Monti et al., 2012). An in-house 
validation confirmed acceptable linearity in the measurement range. This assay 
is not clinically used for dogs and, therefore, no pre-defined cut-off value for 
diagnosis of decreased GFR was available. A “defined” cut-off yielding a 
sensitivity equal to that of creatinine was therefore chosen for sensitivity and 
specificity analysis.  
6.3.2 Capillary electrophoresis and mass spectometry (paper IV) 
Analysis by CE-MS was performed as previously described (Mischak et al., 
2013) using a Beckman Coulter Proteome Lab PA800 capillary electrophoresis 
system online coupled to a microTOF II mass spectrometer (MS; Bruker 
Daltonic, Germany). Peptide abundance was normalised to naturally occurring 
urinary polypeptide standards in order to compensate for differences in USG 
between different urine samples.  
 
 
Fig 9. Urinary capillary electrophoresis coupled to mass spectrometry (CE-MS) work-flow. Urinary 
proteins are detected by CE-MS, where mass and relative abundance of each protein is analysed. 
All detected peptides are stored in a database, allowing further evaluation of peptides for diagnostic 
purposes. Reproduced with permission from Pontillo and Mischak. Urinary peptide-based classifier 
CKD273: towards clinical application in chronic kidney disease. Clinical Kidney Journal (2017) 
10(2):192-201. Published by Oxford University Press on behalf of ERA-EDTA. 
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For peptide sequencing, liquid chromatography-MS/MS (Dionex Ultimate 3000 
RSLC nano flow system, Dionex, UK) and CE-MS/MS were used. Resultant 
MS/MS data was analysed by Proteome Discoverer and compared against the 
Uniprot canine non-redundant database without enzyme specificity (Fig 9). 
6.3.3 Statistical analyses 
Statistical analyses were performed with JMP Pro 11 (SAS Institute, NC, USA), 
MedCalc (Medcalc Software, Belgium), and GraphPad Prism 7.00 (GraphPad 
Software, CA, USA). Study populations were described by medians and 
interquartile ranges. Non-parametric tests were used for comparisons of 
continuous variables between groups. Statistical significance was set at p<0.05. 
If multiple comparisons were made, corrections were applied, either by 
controlling familywise error rate (Bonferroni method, papers II and III) or, in 
paper IV, by controlling the false discovery rate (Benjamini & Hochberg, 1995). 
Simple and multiple regression analyses (papers II and III) were used to 
evaluate associations between dependent variables of interest (cTnI, 
NT-proBNP, creatinine, SDMA and cystatin C concentrations) and different 
clinicopathological variables. Variables linearly associated with the dependent 
variable, and with a p-value of less than 0.2 in the univariate analyses, were 
included in the multiple regression modelling. The final model was constructed 
without interaction terms, in a backward stepwise manner. During this process, 
the variable with the highest p-value was removed in each step until only 
significant (p<0.05) variables remained. The resulting adjusted R2 indicated the 
proportion of variability of the dependent variable that might be explained by 
the independent variables included in the final model. Multiple regression 
analyses were also used to construct models for mGFR-estimation using the 
three investigated biomarkers of GFR. 
Partition analysis was performed in order to create a decision tree for clinical 
estimation of GFR using all available clinicopathologic variables of all dogs in 
paper III. Multiple regression, with mGFR as the dependent variable, and ROC-
curve analysis was performed in order to evaluate added value of multiple 
markers for GFR estimation. 
In paper IV, peptides differentially expressed between cases and controls in 
a training set were used to build classifying models with support vector machines 
(SVM), a software specifically designed to deal with large amounts of data. In 
SVM, each sample was regarded a “p-dimensional” vector where p represented 
the number of peptides in the sample. The SVM algorithm then constructed 
multidimensional separation planes between case and control vectors. The 
hyperplane with the largest distance to the nearest data-points on both sides 
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(=that best separated cases and controls) was selected. Sample classification in 
the validation process (healthy or CKD), was dependent of on which side of the 
hyperplane (case or control side), each vector (=validation set sample) was 
situated.  
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7.1 Kidney-related disease in Swedish dogs (paper I) 
Incidence 
The total number of dogs with a veterinary care insurance in Agria over the years 
1995-2006 was 665,245. These dogs contributed with a total of 2,792,325 
DYAR. The number of dogs with a veterinary claim of KD during the time they 
were insured was 4390. This corresponds to an overall IR for KD of 
15.8 (CI: 15.3-16.2) cases/10,000 DYAR, approximately equally divided 
between female and male dogs. In most cases, the type (aetiology) of KD was 
not specified. The mean (±SD) and median (range) age at which the dogs were 
documented with the first episode of KD was 6.9 ± 3.3 and 7.4 (0-12) years, 
respectively.  
In the breed-specific analysis (which, as previously mentioned, included only 
breeds contributing with > 10.000 DYAR to the Agria database), the Bernese 
mountain dog was the breed with the highest IR of KD (51 cases/DYAR). 
Swedish elkhound, Siberian husky and Finnish spitz were the three breeds with 
the lowest IR of KD (each five cases/DYAR) in this study (Fig. 10). In three 
breeds (flat-coated retriever, collie and golden retriever), female dogs had 
significantly higher IRs of KD than male dogs. There was no consistent change 
in yearly incidence rate of KD in this population of dogs insured over the years 
1995-2006.  
 
 
7 Main results 
56 
 
 
 
Fig 10. Incidence rates (cases/10,000 DYAR with 95% confidence intervals) of kidney-related 
disease in breeds with significantly higher or lower incidence rates than the average rate 
(15.8 cases/10,000 DYAR). DYAR; dog years at risk, SCWT; soft-coated wheaten terrier, CKCS; 
cavalier King Charles spaniel, Eng spr sp; English springer spaniel; Germ wire pointer, German 
wirehaired pointer. 
Mortality 
The total number of dogs with mortality insurance at Agria over the years 1995-
2006 was 548.346. These dogs contributed with a total of 2.036.398 DYAR. Of 
these dogs, 1981 died because of KD, which corresponds to a total mortality rate 
of KD of 9.7 (CI: 9.3-10.2) deaths/10,000 DYAR. The total mortality rates for 
female and male dogs were 10.8 (CI: 10.2-11.5) and 8.6 (CI: 8.0-9.2) 
deaths/10,000 DYAR, respectively. Most commonly, the aetiology of KD 
leading to death of the dogs was not specified. The mean (±SD) and median 
(range) age at which the dogs died from KD was 6.6 ± 2.6 and 7.1 (0-10) years, 
respectively.  
The Bernese mountain dog was the breed with the highest 
(49 cases/10,000 DYAR) and miniature dachshund the breed with the lowest 
(2 cases/10,000 DYAR) mortality rates of KD. In four breeds (Bernese mountain 
dog, flat-coated retriever, boxer and golden retriever), female dogs had 
significantly higher MRs of KD than male dogs. 
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7.2 Study population characteristics (papers II-IV) 
The exact number of dogs included in the studies II-IV are shown in Fig 7. In 
total, 36 healthy dogs and 75 dogs with diagnosed or suspected CKD contributed 
with data to the studies. Of the dogs, 14 were mixed breeds, six were Labrador 
retrievers, six were golden retrievers, five were boxers and four or less were of 
52 other breeds. The age of included dogs ranged between four months and 14.5 
years. 
7.3 Circulating biomarkers (papers II and III)  
7.3.1 Biomarkers of cardiovascular homeostasis  
N-terminal pro-B-type natriuretic peptide 
In the univariate analyses, NT-proBNP increased with increasing plasma volume 
(PVf/kg), UPC, and creatinine concentration and with decreasing PCV, mGFR 
and albumin concentration. The two variables independently associated with 
NT-proBNP in this study were packed cell volume (PCV) and PVf/kg 
(R2adj = 0.42; p< 0.001). Concentrations of NT-proBNP in dogs in different 
stages of CKD and association between NT-proBNP concentration and mGFR 
are shown in Fig 11. 
 
 
  
Fig 11.  A. Concentrations of NT-proBNP in 23 healthy dogs and 27 dogs with CKD (stages 1-3). 
B. NT-proBNP increased with decreasing mGFR but this effect was not retained in the multiple 
regression analysis.  
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Cardiac Troponin I 
In the univariate analyses, cTnI increased with increasing age, SBP, PVf/kg, BW 
and creatinine concentration. The three variables independently associated with 
cTnI in this study were age, SBP and BW (R2adj = 0.50; p< 0.001). 
Concentrations of cTnI in dogs in different stages of CKD and association 
between cTnI concentration and mGFR are shown in Fig 12. 
 
 
 
Fig 12. A. Concentrations of NT-proBNP in 23 healthy dogs and 27 dogs with CKD (stages 1-3). 
B. There was no association between cTnI and mGFR in 23 healthy dogs and 27 dogs with CKD.  
7.3.2 Biomarkers of decreased GFR  
Creatinine 
The AUC of the creatinine concentration for detection of decreased mGFR 
(according to the pre-specified hospital mGFR cut-off <30.8 ml/min/L) was 
0.98 (0.93-1.0) and the AUC for detection of mGFR below 37 ml/min/L was 
0.94 (0.87-0.98). The “optimal” cut-off for detection of decreased GFR (<30.8 
ml/min/L) in the dogs of this study was 127 µmol/L. Applying the pre-defined 
cut-off of 115 µmol/L, sensitivity and specificity of creatinine for diagnosis of 
decreased GFR (<30.8 ml/min/L) was 90% and 90%, respectively.  
Ten dogs were falsely categorised with regard to mGFR status, using 
creatinine concentration with the pre-defined cut-off value. In Table 1A, SDMA 
and cystatin C concentrations in the 10 dogs falsely classified by creatinine, are 
shown. Measured GFR, BW, PCV, and phosphate concentration were the 
variables independently associated with creatinine concentration 
(R2adj=0.74; P<0.0001).  
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Symmetric dimethyl-arginine 
The AUC of SDMA for detection of decreased GFR (according to the pre-
specified hospital mGFR cut-off <30.8 ml/min/L) was 0.96 (0.91-0.99) and the 
AUC for detection of a mGFR below 37 ml/min/L was 0.94 (0.87-0.98). The 
“optimal” cut-off for detection of decreased GFR in the dogs of this study was 
16 µg/dL. Applying the pre-defined cut-off of 14, sensitivity and specificity of 
SDMA for diagnosis of decreased GFR (<30.8 ml/min/L) was 90% and 87%, 
respectively.  
Twelve dogs were falsely categorised with regard to mGFR status using 
SDMA concentration with the pre-defined cut-off value. In Table 1B, the 
creatinine and cystatin C concentrations in the 12 dogs falsely classified by 
SDMA, are shown. 
There was a difference between concentrations of SDMA in healthy dogs, 
and dogs in IRIS stages 1-3 of CKD (except between stage 2 and 3). Stage 4 
dogs were too few to be included in the statistical comparison of biomarker 
concentrations between groups. Measured GFR, phosphate concentration, 
albumin concentration and USG were the variables independently associated 
with SDMA concentration (R2adj=0.71; P<0.0001). 
Cystatin C 
The AUC of cystatin C for detection of decreased GFR (according to the pre-
specified hospital mGFR cut-off <30.8 ml/min/L) was 0.87 (0.79-0.93) and the 
AUC for detection of mGFR below 37 ml/min/L was 0.83 (0.74-0.90). The 
“optimal” cut-off for detection of decreased GFR in the dogs of this study was 
0.47 mg/L. Applying the “defined” cut-off of 0.49 mg/L, corresponding to the 
same sensitivity as creatinine (90%), specificity of cystatin C concentration for 
diagnosis of decreased mGFR (<30.8 ml/min/L) was 75%. There was a 
difference between concentrations of cystatin C in healthy dogs, and dogs in 
IRIS stages 1-3 of CKD (except between stage 1 and 2). Measured GFR, age, 
PCV, calcium concentration and USG were the variables independently 
associated with cystatin C concentration (R2adj=0.62; P<0.0001).  
Multivariable analyses for estimation of mGFR 
The combination of creatinine and SDMA concentrations for detection of 
decreased mGFR in a multiple regression model resulted in an adjusted R2 of 
0.67 and an AUC of 0.98. For the combination of creatinine and cystatin C 
concentrations, adjusted R2 was 0.65 and the AUC was 0.99. When creatinine, 
SDMA and cystatin C concentrations were all used to construct a model, 
adjusted R2 was 0.68 and AUC was 0.99. In the partition model (Fig 13) for 
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diagnosis of decreased mGFR, the resulting decision tree contained only 
creatinine and cystatin C. At one location in the decision tree, cystatin C was 
interchangeable with BW (red boxes).  
 
Table 1. Results of other markers in dogs falsely categorised (by creatinine and SDMA) dogs 
A) Dogs misclassified by creatinine      
 
Breed 
mGFR 
ml/min/L 
(30.8) 
Creatinine 
µmol/L 
(115) 
SDMA 
µg/dL 
(14) 
Cystatin C 
mg/L 
(0.51) 
Greyhound 43 136 13 0.49 
Greyhound 43 125 13 0.23 
Labrador retriever 41 117 11 0.43 
Large Swedish hunting breed 49 121 14 0.98 
Bernese mountain dog 43 117 16 0.62 
German shepherd 33 116 14 0.36 
Cane corso 36 120 14 0.41 
Bedlington terrier ↓   29 105 16 0.51 
Small mixed breed ↓   27 104 12 0.58 
Tibetan terrier ↓   25 100 14 1.54 
B) Dogs misclassified by SDMA  
 
Breed 
mGFR 
ml/min/L 
(30.8) 
SDMA 
  µg/dL   (14) 
Creatinine 
µmol/L 
(115) 
Cystatin C 
    mg/L 
(0.51) 
Golden retriever 44 15 92 0.53 
Golden retriever  73 15 76 0.23 
Mops 38 15 110 0.73 
Kerry blue terrier 47 15 90 0.39 
French bulldog 47 16 61 0.32 
Soft-coated wheaten terrier 48 15 81 0.89 
Boxer 38 19 78 0.38 
Bernese mountain dog 43 16 117 0.62 
Large mixed breed 47 15 73 0.44 
Basenji ↓   29 13 127 0.50 
Small mixed breed ↓   27 12 104 0.58 
Tibetan terrier ↓   25 14 100 1.54 
     
A) Breed, measured GFR (mGFR) and creatinine, SDMA and cystatin C concentrations in the 10 
dogs falsely categorised by creatinine with regard to mGFR status (cut-off 30.8 ml/min/L). 
B) Breed, mGFR and SDMA, creatinine and cystatin C concentrations in the 12 dogs falsely 
categorised by SDMA with regard to mGFR status. Green-coloured fields indicate a “correct” result 
and red fields indicate an “incorrect” result, with regard to mGFR status.  
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Fig 13. Resultant decision tree in partition modelling for estimation of mGFR-status in clinically 
stable dogs. Percentages represent proportion of dogs in each box with mGFR >30.8 ml/min/L, 
(“normal”). Creatinine, SDMA and cystatin C concentrations were all included as independent 
variables, but SDMA concentration was not used in the final algorithm. The resultant decision tree 
was identical when all available clinical variables were included, but bodyweight was 
interchangeable with cystatin C concentration for partitioning dogs with a creatinine concentration 
≥127 µmol/L (red boxes).  
7.4 Urinary CE-MS analysis (paper IV) 
 
In total, 5398 different peptides were identified in all samples (Fig 14). One 
hundred and thirty-three peptides were differentially excreted between healthy 
dogs and those with CKD (Fig 15). Of these 133 peptides, 35 were sequenced, 
and most (n=32) were fragments of collagen I (α1 or α3 chains), one was a 
fragment of collagen IV and two were fragments of uromodulin. Two peptide 
models were developed, one (133P) containing all 133 differentially expressed 
peptides, and one (35P) containing all 35 differentially expressed peptides that 
were sequenced in the present study. Both models predicted disease status 
(healthy vs CKD) of the dogs in the independent validation cohort with an AUC 
of 0.88 (95% CI: 0.72-1.0). Two out of the three inconclusive dogs were 
characterised as healthy and one was characterised as CKD.  
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Fig 14. All 5398 identified peptides in urine samples from 50 dogs, with and without CKD, in paper 
IV. Peptide molecular mass is three-dimensionally plotted against normalised capillary 
electrophoresis migration time. 
 
 
Fig 15. Differentially expressed peptides (n=133) in healthy dogs and dogs with chronic kidney 
disease, in paper IV. Peptide molecular mass is three-dimensionally plotted against normalised 
capillary electrophoresis migration time. 
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8.1 Epidemiology of CKD  
The overall IR of KD in this large dog population was 15.8 cases/10,000 DYAR. 
Incidence rates of a few other diseases have been calculated in similar 
populations of dogs in the Agria database: The IR of KD was similar to that of 
atopic dermatitis (17 cases/10,000 DYAR) and approximately half of the IR of 
intervertebral degenerative disc disease (27.8 cases/10,000 DYAR) (Bergknut et 
al., 2012; Nodtvedt et al., 2006). The IR of KD was however less frequent than 
dystocia (57 cases/10,000 DYAR) and pyometra (199 cases/10,000 DYAR) 
(Jitpean et al., 2012; Bergstrom et al., 2006), which were both calculated using 
only female dogs at risk. The mortality rate of KD was 9.7 deaths per 10.000 
DYAR, which was similar to the MR of intervertebral disc disease 
(9.4 deaths/10,000 DYAR) and about half of the MR of heart disease 
(21.4 deaths/10,000 DYAR) in previous studies on dogs in the Agria database 
(Bergknut et al., 2012; Egenvall et al., 2006).  
Animal health insurance databases, unlike hospital data, contain information 
about the whole population at risk (which is necessary in order to investigate 
incidence rates of disease) and not only information regarding clinical events. 
However, interpretation of IRs beyond comparison of incidence between 
different diseases may be difficult. In paper I, an alternative interpretation was 
discussed, in that 10,000 DYAR might represent 1000 dogs (each living 10 
years). Of these, approximately 16 dogs developed KD, which equals a 
cumulative proportion, or period prevalence, of 1.6 %.  
All epidemiologic measurements of KD frequency are likely to represent 
underestimations of the truth because of the insensitivity of current diagnostic 
methods. However, this probably affects prevalence measurements more than 
incidence rates. Misdiagnosis is another possible source of error in insurance 
8 General discussion  
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database analysis, which may result in both under- and overestimation of disease 
occurrance. Because of limited data resolution, the occurrence of misdiagnosis 
cannot be controlled. Validity of secondary databases may vary, but it can be 
high, depending on how similar the purpose of data collection was to the research 
question at hand (Egenvall et al., 2009). A validation of data against veterinary 
practice records has been performed, and agreement between information in 
practice records and in the Agria database was excellent for information 
regarding breed and sex and fair for information regarding date of birth and for 
specific diagnoses (Egenvall et al., 1998). Possibly, choice of specific insurance 
companies by owners of some breeds, may also influence results. 
In the breed-specific analysis of paper I, it was shown that a number of dog 
breeds had a higher, and some breeds a lower, incidence rate of KD than the 
population as a whole. The IR of KD in the Bernese mountain dog, 
51 cases/10,000 DYAR, was over three times as high as the IR of all dogs 
(15.8 cases/10,000 DYAR). Shetland sheepdog, one of the breeds in which KD 
has previously not been recognised as frequent, was shown in paper I to have a 
high IR and MR of KD. For Shetland sheepdog, the IR was 31 cases/10,000 
DYAR, which was twice as high as the average of all breeds. The MR of KD for 
this breed was the second highest of all included breeds, >2.5 times the average 
MR. This type of information may help in diagnostic decision making when 
assigning different probabilities to relevant differential diagnoses for an 
individual under investigation. Importantly, in order not to introduce bias, many 
breeds were not included in this comparison because the number of DYAR was 
considered too low to allow meaningful data. 
8.2 Cardiovascular-renal interaction 
In paper II, it was shown that neither NT-proBNP nor cTnI concentration were 
independently associated with GFR. As GFR decreases in CKD, circulating 
volume status and myocardial cell integrity may both be affected. In this 
situation, circulating concentration of NT-proBNP and cTnI are expected to 
change accordingly. If, however, passive accumulation of these biomarkers 
occurs, the diagnostic value for detection of cardiovascular pathology is 
lessened. According to the results of paper II, neither of these markers passively 
accumulate as GFR decreases in dogs with stable CKD. The situation may 
however be different for dogs with acute or acute-on-chronic kidney disease. 
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Circulating volume status 
In paper II, circulating volume (PVf/kg) was shown to increase with decreasing 
mGFR. This might explain an increase in NT-proBNP concentration with 
decreasing mGFR in dogs without cardiac pathology (Fig 11 B), because 
NT-proBNP is released in response to cardiac stretch, irrespective of underlying 
reason. Changes in circulating volume secondary to CKD is one example and 
might possibly explain increased concentrations of NT-proBNP in at least some 
of the dogs with renal compromise described in previous studies (Raffan et al., 
2009; Schmidt et al., 2009; Boswood et al., 2008).  
In addition to the effect of different disease states on concentrations of 
NT-proBNP, this marker has also been shown to differ considerably between 
breeds and to have a comparably high individuality (Ruaux et al., 2015; 
Sjostrand et al., 2014). Consequently, interpretation of a single NT-proBNP 
result from an individual dog in a clinical situation in relation to suggested, 
population-based, clinical cut-offs should be done with caution. As for all tests, 
knowledge of disease pathophysiology and performance characteristics of the 
test are important for optimal interpretation of test results.  
 
Myocardial cell integrity 
In paper II, cTnI concentration was higher in the dogs with CKD (as a group), 
than in healthy dogs. There was, however, no association between cTnI and 
mGFR (Fig 12 B). Subclinical myocardial cell damage is a plausible reason for 
the (comparably small) increases in circulating concentrations of cTnI observed 
in some of the dogs in this study. As discussed in section 3.5, subclinical 
myocardial damage of unknown aetiology occurs in people with CKD as well. 
Earlier observations (Silvestrini et al., 2012; Ljungvall et al., 2010; Serra et 
al., 2010) of an age-dependence of cTnI concentration in dogs were confirmed 
in the multiple regression analysis in paper II. However, the absolute increase of 
cTnI with age in the healthy population was comparably small (lower than the 
limit of detection for many cTnI assays used in the clinic), and therefore 
probably negligible when this analysis is used clinically to assess myocardial 
cell integrity.  
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8.3 Diagnosis of CKD  
8.3.1 GFR assessment 
Overall diagnostic value of SDMA and cystatin C 
In paper III, ROC-curve analysis was used to investigate the overall diagnostic 
value of SDMA and cystatin C concentrations as markers of decreased GFR. 
The overall value of SDMA was similar to that of creatinine. The value of 
cystatin C as a marker of mGFR was, however, inferior to both creatinine and 
SDMA. These results may appear disappointing, but most (or all) surrogate 
markers of GFR are expected to perform approximately as creatinine does. The 
association between concentration of circulating biomarkers and GFR is 
expected to be non-linear and best described by an exponential function.  
Clinical cut-offs for creatinine, SDMA and cystatin C 
Results of ROC-curve analyses, although recommended for comparison between 
different tests, have little direct relevance for interpretation of results in the 
clinical use of biomarkers. In order to calculate properties of biomarker tests, 
such as sensitivity and specificity, cut-off values are used. In paper III, cut-offs 
to indicate decreased GFR for creatinine and SDMA were obtained from the 
laboratories where analyses were performed, the University Animal Hospital in 
Uppsala for creatinine (115 µmol/L), and Idexx Laboratories in Germany for 
SDMA (14 mg/dl). The sensitivity of creatinine and SDMA was exactly the 
same (90%) when applying these cut-offs, and the specificities very similar 
(90% versus 87%), in accordance with the ROC-curve analysis. A “defined” cut-
off for cystatin C, which corresponded to an identical sensitivity as that of 
creatinine (90%), was chosen. The specificity of cystatin C at the defined cut-
off was 75%, again showing the inferior diagnostic value of cystatin C compared 
to the other two markers.  
The cut-offs that corresponded to the “best combination” of sensitivity and 
specificity, identified in the ROC-curve analysis, were slightly higher than the 
pre-defined cut-offs for both creatinine and SDMA (126 µmol/L and 16 mg/dl, 
respectively). By use of the pre-defined, currently clinically used, cut-offs for 
decreased GFR, high sensitivities of the tests are prioritized and consequently, 
specificity is compromised. Cut-offs used to indicate decreased GFR may be 
adjusted depending on desired biomarker performance, keeping in mind that 
sensitivity and specificity depend on each other.  
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Test sensitivity and specificity, although clinically useful in some 
circumstances, are sometimes confused with positive predictive value and post-
test probability, and this may result in diagnostic error. In paper III, interval LRs 
for creatinine, SDMA and cystatin C concentrations are suggested. These ratios 
are used to modify pre-test probability of disease. In a clinical setting, pre-test 
probability refers to the individual dog, taking into account the history, physical 
examination and results of any previous test results. Assessment of pre-test 
probability is important both to the very decision of whether to perform a 
diagnostic test, and to the interpretation of test results. The Fagan nomogram 
(Fig. 16) for Bayes´s theorem may be used to quickly estimate the change of 
disease probability using the LRs of the biomarkers investigated in paper III 
(Fagan, 1975). A straight line is drawn from the pre-test probability through the 
LR, to indicate the post-test probability on the right side of the graph. Evident 
when using the nomogram is that post-test probability, although not immediately 
obvious or intuitive, depends heavily on 
pre-test probability. Because a precise 
estimation of pre-test probability is 
difficult, the nomogram may be used 
qualitatively (Medow & Lucey, 2011). 
Both pre- and post-test probability may 
then be thought of in terms of very 
unlikely, unlikely, uncertain, likely or 
very likely. 
The term “clinical accuracy” has been 
proposed to indicate the ability of a test to 
modulate probability of disease 
(Fanshawe et al., 2018). At least for some 
ranges of results of all three biomarkers 
investigated in paper III, the clinical 
accuracy is very high, as reflected by high 
interval LRs. The exact cut-offs for the 
different intervals of LR of the three 
biomarkers may, however, differ between 
assays.  
Fig 16. Fagan nomogram, used to estimate post-test disease probability when the likelihood ratio 
of a test is known (Fagan T.J. 1975). Likelihood ratios are presented for SDMA, cystatin C and 
creatinine concentrations in paper III.  
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Creatinine 
Results of laboratory tests may vary with certain signalment features of the dog 
under investigation for CKD. As mentioned above, serum creatinine 
concentration is dependent on muscle mass, which in turn differs between dogs 
of different breeds and sizes. Results of paper III support this, as several large 
breed dogs were falsely categorised by creatinine (azotaemia despite mGFR 
below the cut-off value). Also, in three small breed dogs, creatinine 
concentrations were below the cut-off for azotaemia despite a low mGFR 
(Table 1A). If a stable creatinine concentration (=at steady state), regardless of 
the reference interval, does not `match` the muscle mass or breed size of a dog 
with suspected kidney disease, additional tests of GFR may be indicated. This 
can be accomplished by GFR measurement by any available method, or by use 
of other indirect biomarkers of GFR, such as SDMA or cystatin C.  
SDMA 
In paper III, the overall diagnostic value of SDMA was similar to that of 
creatinine. Despite this, SDMA may be of clinical use in selected dogs. 
However, the claim that the concentration of SDMA may be used to detect 
decreased GFR at an earlier point in time of disease development is inaccurate, 
as this depends entirely on where the cut-off is placed. This is similar to the 
situation for most, if not all, quantitative biomarkers including creatinine. 
An example of how SDMA concentration may be used in staging of dogs 
with CKD is provided on the website of IRIS (IRIS, 2016). It is suggested that 
in dogs of IRIS stage 2 with an SDMA concentration persistently above 25 µg/dl, 
GFR may be underestimated by the creatinine concentration. Our results are in 
agreement with this statement. There was a comparably large overlap in SDMA 
concentrations between stage 2 and stage 3 dogs, and in the 12 dogs in IRIS stage 
2, SDMA more accurately than creatinine reflected mGFR (R2 = 0.47 vs 0.19 for 
creatinine). This was not true for the 12 dogs in stage 3, however. In these dogs, 
creatinine reflected mGFR more accurately than SDMA did (R2 = 0.60 vs 0.20 
for SDMA). Further investigations are needed to confirm these differing 
associations of creatinine and SDMA concentration with GFR in other 
populations of dogs in stage 2 and 3. For dogs in stage 1, as well as for healthy 
and inconclusive dogs, neither creatinine nor SDMA concentrations were 
strongly associated with mGFR. This has previously been shown for creatinine 
(van den Brom & Biewenga, 1981). 
As an adjunct test to creatinine, interpreted with the pre-defined cut-off or 
with the interval LRs proposed in paper III, this assay is probably of clinical use 
as a biomarker of GFR in addition to creatinine. However, the proposed interval 
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LRs for SDMA concentration in paper III should be further evaluated in other 
patient populations. 
Cystatin C 
Overall diagnostic performance of cystatin C concentration as a marker of 
decreased mGFR was inferior to both creatinine and SDMA according to paper 
III. The reason for the inferior diagnostic performance of cystatin C is unknown. 
The molecular weight (MW) of cystatin C (13.4 kDa) is substantially higher than 
those of creatinine (0.11 kDa), SDMA (0.20 kDa) and the radiopharmaceutical 
used for scintigraphy (99Tc= 0.99 kDa; DTPA=0.39 kDa). Therefore, differing 
sieving coefficients of these molecules (cystatin C vs creatinine, SDMA and 
99Tc-DTPA) may indicate pathology at the level of the glomeruli (Grubb et al., 
2015). In human medicine, a syndrome referred to as ´shrunken pore syndrome´ 
has recently been identified. This syndrome is suspected when eGFR calculated 
with cystatin C-based equations is ≤ 60% of the eGFR calculated with creatinine-
based equations at the same point in time (Grubb et al., 2015). Shrunken pore 
syndrome is thought to occur because of shrinkage of pores in the glomerular 
filtration barrier, resulting in decreased filtration of molecules with MWs of 
between approximately 6.5-70 kDa, which are normally relatively freely filtered 
(high sieving coefficients) at the glomerulus. Whether the syndrome occurs in 
dogs, and thus might have influenced results of this study, is unknown.  
Individuality is important for diagnostic utility of a test when a population-
based cut-off is used, as in paper III (Petersen et al., 1999). The low individuality 
of cystatin C in comparison with that of creatinine has been considered an 
advantage of cystatin C when used as a marker of GFR in people (Keevil et al., 
1998). Later studies have, however, reported a similar individuality of creatinine 
and cystatin C in people (Carter et al., 2016; Andersen et al., 2010b; 
Bandaranayake et al., 2007). In dogs, individuality of creatinine and cystatin C 
has been shown to be similar in two studies (Pagitz et al., 2007; Jensen & Aaes, 
1993). This needs further investigation because individuality is an important 
property that influences diagnostic value of markers, when evaluated using a 
population-based cut-off value.  
Age was independently associated with cystatin C concentration in paper III. 
In two of the 30 healthy dogs, cystatin C concentration was > 0.5 mg/L (0.55 
and 0.77). These dogs were 12 and 14 years old, respectively. Higher 
concentrations of cystatin C in older dogs without disease of the kidneys have 
been shown in some studies (Monti et al., 2012; Braun et al., 2002), but in others 
no effect of age was seen (Miyagawa et al., 2009; Wehner et al., 2008). 
Evaluations of a potential age-dependence of cystatin C as well as of other 
markers of GFR are complicated by the possibility of age-related subclinical 
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decline of GFR in healthy individuals. In this study the increase in cystatin C 
concentration with age was independent of mGFR and therefore, age might be 
taken into consideration if this PETIA assay with a clinical cut-off value of 0.5 
mg/L is used (as in the partition model, Fig 13). If the higher clinical cut-off of 
0.9 mg/L is used (as in the proposed interval LRs in paper III) however, the 
effect of age can probably be ignored. The cystatin C-concentration was above 
0.9 mg/L in only one of all dogs with mGFR below the cut-off value (n=68). 
Advantages with the cystatin C-assay used in paper III are the commercial 
availability of the reagent and the fact that it can be analysed in biochemistry 
instruments that are already in use at many clinical laboratories. As an adjunct 
test to creatinine concentration, interpreted by the partition analysis (decision 
tree) or the interval LRs proposed in paper III, this assay might be of clinical use 
in selected patients. However, all proposed clinical cut-offs for cystatin C 
concentration in paper III should be further evaluated in other patient 
populations. As noted above, age of the dog under investigation should be taken 
into consideration in the interpretation of cystatin C concentrations, especially 
when using the decision tree.  
Value of SDMA and cystatin C as additional markers of GFR  
As shown in Table 1A, SDMA (or cystatin C) analysis in addition to creatinine 
concentration may increase diagnostic yield for individuals that are falsely 
categorised by creatinine. Many of these dogs were either large or tiny, with 
large or small muscle mass, respectively. No unifying patient characteristics 
could be identified that could aid in identifying dogs that may be falsely 
categorised using the SDMA-test, however (Table 1B). In this regard, the 
dependence on muscle mass (that is usually considered a drawback for 
creatinine) may be considered a slight advantage, in that it is known when to 
doubt a particular creatinine result, but not when to doubt an SDMA-result. This 
is clinically relevant, as the SDMA test falsely categorised (with regard to 
mGFR) approximately the same number of dogs as did the creatinine test. Both 
markers are valuable, but a reasonable recommendation could be to depend on 
creatinine as the primary test of GFR and to interpret SDMA concentration in 
light of creatinine concentration.  
When Table 1 (falsely categorised dogs) was constructed, mGFR for each 
dog was known. This is usually not the case in a clinical situation. It would be 
interesting to prospectively investigate the value of adding SDMA and cystatin 
C concentrations to the clinical investigation of dogs for which the creatinine 
concentration is suspected to be a less reliable indicator of GFR, as in the 
evaluation of a large dog with mild azotaemia, or a small or emaciated dog with 
a creatinine concentration close to the cut-off value for decreased GFR.  
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Value of multiple clinicopathological variables for GFR assessment 
In diagnostic accuracy studies, the value of tests are usually investigated as if 
the test-result had to stand on its own. This is seldom the case in a clinical 
situation. The construction of diagnostic models including other available 
clinical information in the evaluation of diagnostic tests has been encouraged in 
order to improve diagnostic research (Moons et al., 1999). In paper III, available 
clinicopathological variables from all dogs were included in the partition model 
for diagnosis of decreased mGFR. Only creatinine and cystatin C appeared in 
the resultant decision tree. The interpretation of this is that, overall, SDMA 
concentration does not offer much new information when creatinine 
concentration is already known. In accordance with this, creatinine 
concentration (with different cut-offs) was the only variable left in the decision 
tree if only SDMA and creatinine were entered into the model (data not shown). 
However, as discussed above, for some dogs, SDMA is probably highly valuable 
as an adjunct test.  
The three GFR biomarkers (creatinine, SDMA and cystatin C) were also 
entered into multiple regression models with mGFR as the dependent variable. 
Addition of SDMA to creatinine only marginally improved model performance 
(adjusted R2 of 0.67 for creatinine and SDMA together, compared to the R2 for 
either marker alone; 0.62). The same was true when instead adding cystatin C 
(R2 = 0.46) together with creatinine (R2adj=0.65), and when including all three 
biomarkers as variables in the model (R2adj=0.68). The resultant AUCs of 
different combinations of biomarkers in ROC-curve analyses were also very 
similar to each other, and to the AUC of creatinine alone (0.98). This supports 
the results in the initial ROC-curve analysis; that overall diagnostic value of 
creatinine and SDMA is similar. This may be interpreted as supportive of the 
main finding of paper III, that the overall value of adding SDMA or cystatin C 
to creatinine is rather low. The proposed value of marker combinations for 
selected individuals, however, might possibly explain the slight improvements 
in adjusted R2 for combinations of markers compared to the R2 for each 
individual marker alone.   
Association of age and bodyweight with glomerular filtration rate 
There was no association between age and mGFR, or between BW and mGFR, 
in the 30 healthy dogs (or in all dogs with mGFR > 30.8 ml/min/L, n=68) 
included in paper III. On average, small breed dogs have higher GFR than large 
breeds do (Miyagawa et al., 2010; Bexfield et al., 2008). The fact that only four 
of the 68 dogs with mGFR above the cut-off value in paper III weighed >35 kg 
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might explain the lack of a negative association between BW and GFR in 
paper III.  
An age-related decrease in GFR in small dogs (<12.4 and <15.1 kg, 
respectively) has previously been shown (Miyagawa et al., 2010; Bexfield et al., 
2008). Among included dogs in paper III, no association was evident between 
age and mGFR in healthy dogs, or in the 68 dogs with mGFR > 30.8 ml/min/L. 
Neither was there an association between age and mGFR when analysing dogs 
<15 kg (with mGFR > 30.8 ml/min/L, n=19) separately.    
8.3.2 Urinary capillary electrophoresis and mass spectrometry 
In paper IV, 133 naturally occurring peptides that were differentially present in 
urine from dogs with and without CKD were identified. The classifying model, 
133P, constructed and validated in a separate cohort of dogs, could separate dogs 
with CKD from healthy dogs with a sensitivity of 80% and a specificity of 80%. 
These results may be compared to those of the human counterpart of the 133P-
model (CKD273) when applied to the first validation group of people (Good et 
al., 2010). In that study, the sensitivity of the CKD273-model was 85% (95% 
CI: 75-91) and the specificity 100% (95% CI: 91-100). In total, 230 patients with 
CKD and 379 “seemingly healthy” people were used to create the CKD273-
model. With increasing data from dogs, classification may further improve, 
because the number of applicable polypeptides depend on the number of cases 
in the model construction cohort (Weissinger et al., 2004). On the other hand, 
the control dogs used in paper IV were all very well characterised, in contrast to 
the controls in the corresponding human study, and that may have reduced the 
risk of “noise” that might have been introduced by possibly including control 
individuals with subclinical disease.  
One possible reason for false positive and negative results in a diagnostic 
accuracy study, such as paper IV, is that the new test under investigation (CE-
MS) actually performs better than the reference test (clinical evaluation using 
serum creatinine concentration, scintigraphy, urinalysis and renal US). Also, 
CKD aetiology and progression mechanisms may be of importance for results. 
One of the two dogs falsely characterised by the 133P-model as healthy was 
diagnosed with polycystic kidney disease (PKD). This is a disease in which 
multiple cysts grow and gradually replace the renal parenchyma. It is possible 
that the pathophysiology of PKD, on a molecular level, differs from that of many 
other aetiologies of CKD. In the study in which the CKD273-model was 
constructed, PKD was not mentioned among the different CKD aetiologies of 
included people (Good et al., 2010).  
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Urine from three inconclusive dogs were analysed by CE-MS analysis in 
paper IV. Two of these dogs, included because of abnormal renal architecture 
detected by ultrasound, were classified as “healthy” by the 133P-model, and 
neither dog had evidence of reduced renal function on follow-up examinations 
(creatinine concentration only) at least two years after study inclusion. The third 
dog was included six months after treatment of pyelonephritis. At the time of 
inclusion, this dog was non-azotaemic, non-proteinuric and the total GFR was 
> 30.8 ml/min/L. Renal ultrasound was unremarkable. Therefore, this dog was 
not included in the “CKD-group”. However, the mGFR of the left kidney, 
15 ml/min/L, was half of that of the right kidney, 34 ml/min/L (which would not 
have been appreciated using only routine diagnostics), and the 133P-model 
categorized this dog as CKD. At the follow-up visit two and a half years after 
inclusion, the dog was considered healthy by the owners. The mGFR of the left 
kidney was similar to the first measurement (14 ml/min/L), but mGFR of the 
right kidney was at this point similar to that of the left kidney (19 ml/min/L). 
Total mGFR was, however, still above the cut-off at 30.8 ml/min/L and serum 
creatinine concentration was not increased compared to the concentration at 
study inclusion. Our interpretation is that this dog might have had slowly 
progressive CKD at inclusion, as reflected by the 133P-model, but that was not 
detectable with routine diagnostic methods. Further clinical follow-up is planned 
for all three dogs. 
Differences in urine concentration of samples (pre-renal influences) was 
controlled for by normalisation of peptides to internal standard peptides when 
peptide abundance was assessed in paper IV. Normalisation may be performed 
in different ways in urine. One study using CE-MS compared normalisation to 
urinary creatinine concentration or exogenous stable isotope-labelled peptide 
standards (absolute quantification), with normalisation to highly abundant 
collagen fragments, “internal peptides”, by ion counting (relative 
quantification). The results indicated that relative identification using internal 
peptides was a reasonable alternative. Adding exogenous isotope-labelled 
peptides did not appear to confer any additional benefit (Jantos-Siwy et al., 
2009).  
The addition of a urinary proteomic-based model for detection of CKD could 
be useful in a clinical situation as an adjunct to the routine diagnostic methods 
currently available (Fig 17). This is especially true for tubulointerstitial disease 
without proteinuria, which is usually limited to comparably late stages of 
disease.  
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Fig 17. Detection of molecular processes related to fibrosis may provide a future diagnostic 
option for early diagnosis of canine CKD, compared to the markers of glomerular filtration rate 
used today. SDMA; symmetric dimethyl arginine, ECM; extracellular matrix, CE-MS; capillary 
electrophoresis and mass spectrometry. 
The urinary peptidome in intrarenal fibrosis 
As mentioned in section 4.3.2, peptides identified in the CE-MS process are 
naturally occurring in the urine. No proteolytic step (that produces “artificial” 
peptides) is needed during sample preparation (Mischak et al., 2013). Detection 
of changes in the urinary peptidome that may be linked to CKD  not only 
provides an exciting new alternative way of early diagnosis to explore further, 
but may also shed some light on pathophysiological mechanisms contributing to 
renal damage. In paper IV, 30 out of the 133 differentially expressed peptides 
used to create the 133P-model were sequenced. Most peptides (n=32) were 
fragments of collagen I, one peptide originated from collagen IV and two were 
uromodulin (previously called Tamm-Horsfall mucoprotein) fragments. All 
peptides were present in lesser amounts in dogs with CKD than in healthy dogs. 
Fragments of collagen are abundant in the human urinary peptidome as well, 
and probably reflect physiological turnover of the ECM (Coon et al., 2008). The 
renal ECM is composed of collagen type I, III, V, VI and XV, polysaccharides, 
glycoproteins and glycosaminoglycans (Bosman & Stamenkovic, 2003). In the 
process of renal fibrosis, excessive intrarenal accumulation of these components 
occurs. Collagen I and III have been shown to accumulate early after an insult 
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to the kidneys in people and rats (Johnson et al., 2002; Sharma et al., 1993). 
Among the peptides differentially expressed between people with CKD and 
healthy controls, fragments of collagen type I are present in lower amounts in 
CKD, similar to the result in the dogs in paper IV (Roscioni et al., 2013; Alkhalaf 
et al., 2010; Good et al., 2010). This decrease in collagen fragment abundance 
is thought to reflect attenuation of extra-cellular matrix degradation by proteases, 
resulting in intrarenal fibrosis that constitutes the common pathway in 
progressive CKD of different aetiologies (Rossing et al., 2008; Eddy & Neilson, 
2006). Collagen fragments have been shown to represent valuable peptidomic 
biomarkers for early CKD detection in people (when healthy individuals and 
those with CKD are to be distinguished), but less valuable in peptide classifying 
models constructed with the aim to differentiate different aetiologies of kidney 
diseases from each other (Siwy et al., 2016).  
Fragments of uromodulin, which is found in renal tubules of people and dogs, 
were less abundant in the urine of dogs with CKD than in the healthy ones in 
paper IV. Intact uromodulin has been shown to be less abundant in urine of 
people with CKD than in healthy ones (Chakraborty et al., 2004). Recent studies 
have proposed a role of uromodulin in the development of intrarenal ECM 
deposition by early tubular back-leakage, leading to abnormal interstitial 
uromodulin deposition inducing inflammation, subsequent fibrosis and 
progression of CKD (Prajczer et al., 2010). A possible link between this role of 
uromodulin in fibrosis and the decrease in uromodulin fragments in CKD dogs 
in paper IV needs further investigation. 
The human peptidome model CKD273, although initially created for early 
diagnosis of CKD, was subsequently shown to be strongly associated with CKD 
progression, further strengthening the hypothesis that the differentially 
expressed peptide fragments reflect an ongoing intrarenal fibrosis process 
(Schanstra et al., 2015; Gu et al., 2014; Argiles et al., 2013; Roscioni et al., 
2013). A potential association between the 133P-model and progression was not 
possible to assess in paper IV because of its cross-sectional design. Although 
there was a time aspect to the diagnosis of CKD (≥ three months), it was not 
known for every included dog if they had progressive or non-progressive 
disease. Included dogs are followed up in order to assess this aspect at a later 
date.  
A possible detection of ongoing intrarenal fibrosis by the 133P-model is 
intriguing, because if this model is further validated and found useful, the 
peptides that comprise this classifying model may be perceived as “active kidney 
injury biomarkers”. Such markers detect the recurrent (or sustained) injury 
suggested to characterise progressive CKD. A call for investigation of active 
kidney injury markers in veterinary medicine was recently made (Cowgill et al., 
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2016). These authors also speculate that a panel of biomarkers probably will be 
needed to detect both active insult and recovery processes. Similarly, because of 
the substantial heterogeneity of CKD, the application of diagnostic panels 
containing multiple biomarkers has been advocated for urinary proteomics 
(Klein et al., 2016; Fliser et al., 2007). Specifically in CE-MS analysis, it was 
shown that classifying models that contained fewer peptides consistently under-
performed compared to models with larger numbers of peptides, probably as a 
result of overfitting (Mischak et al., 2013). Therefore, the 133P-model 
(containing 133 peptides) may have more potential than the 35P model 
(containing only the 35 sequenced peptides) that was also constructed in 
paper IV. 
The potential for early diagnosis of CKD using a marker that probably detects 
ongoing fibrosis depends on when in the process of CKD the fibrotic process 
starts. The ambition of this project was to include dogs primarily in the early 
stages of CKD, in order to investigate early diagnosis. Consequently, many dogs 
with CKD were in stage 1 or 2 on the day of inclusion. Thus, the 133P-model 
was constructed using individuals with comparably early disease (at least 
considering the diagnostic options in clinical use today). Data from clinical 
studies in people with CKD also argue for a significant involvement of fibrosis 
in mild or subclinical stages of CKD (Argiles et al., 2013; Prajczer et al., 2010; 
Rossing et al., 2008). Additionally, a prospective longitudinal study of normo-
albuminuric people with diabetes mellitus showed that the CKD273-model 
predicted progression to macroalbuminuria (the hallmark of diabetic 
nephropathy) 3-5 years earlier than did the current clinical screening method, 
microalbuminuria (Zurbig et al., 2012). 
8.4 Clinical implications  
8.4.1 Epidemiology of kidney disease  
Knowledge of breed differences regarding the occurrence of kidney disease may 
be of help in the diagnostic reasoning process in the clinic. In paper I, KD was 
estimated to have affected about 1.6 % of insured dogs over a 12 year period, 
based on data from the largest animal insurance company in Sweden. This 
estimate is in line with a previous suggestion regarding overall (point) 
prevalence (of CKD only; 0.5-1.5%), but both are probably conservative 
estimates because of the insensitivity of routine diagnostic methods for detection 
of both AKI and CKD (Brown, 2007). For a number of breeds, the entire 95% 
CI of both IR and MR were above the overall (total) IR and MR of KD: Bernese 
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mountain dog, boxer, Shetland sheepdog, miniature schnauzer, flat-coated 
retriever, soft-coated retriever, Rottweiler, cairn terrier and cavalier King 
Charles spaniel.  
The Swedish elkhound, German wiredhaired pointer, mixed breed and 
Finnish spitz were the breeds for which the 95% CI of both IR and MR of KD 
was below the overall (total) IR and MR, respectively.  
This breed analysis is not to be considered an exhaustive investigation, 
because for many (numerically smaller) breeds, there were not enough dogs 
insured at Agria over the years 1995-2007. Including breeds with fewer 
registered individuals could have produced very inaccurate results regarding 
single breed IR and MR. 
8.4.2 Evaluation of cardiovascular function in CKD patients 
An increase in circulating volume (as assessed by a calculated factor related to 
plasma volume) was shown to be associated with a decreasing mGFR in the dogs 
of paper II. As a probable consequence, NT-pro-BNP concentrations increased. 
In 43 of the 50 dogs in paper II (including all healthy dogs), NT-proBNP 
concentration was <900 pmol/L, which should be interpreted as “low risk of 
heart failure” according to information provided by the laboratory. In four dogs, 
NT-proBNP concentrations were within the 900 and 1800 pmol/L range, 
referred to as a grey zone by the laboratory. In three dogs, concentrations of 
NT-proBNP were increased (2167, 3173 and 7274 pmol/L) above the cut-off 
value (1800 pmol/L) that signifies a high suspicion of heart failure. The dog with 
the highest NT-proBNP concentration was diagnosed with protein-losing 
nephropathy, IRIS stage 3 CKD. All dogs were free of significant heart disease.  
Assessment of NT-proBNP is probably not of value for routine clinical 
investigation of dogs with suspected CKD. Rather, the interpretation of this 
study is that NT-proBNP can be used for evaluation of cardiovascular 
compromise in dogs with a diagnosis of CKD. Interpretation of a single 
NT-proBNP-result in a dog needs consideration of different possible reasons for 
increased circulating volume. In addition to this, concentrations in healthy dogs 
vary considerably between breeds and between individuals (Ruaux et al., 2015; 
Sjostrand et al., 2014). 
There was no association between cTnI concentration and mGFR, and no 
evidence for passive accumulation of cTnI concentration with decreasing 
mGFR. The conclusion was that cTnI reflects myocardial cell damage similarly 
in dogs with or without CKD. The interpretation of results of cTnI-analysis, 
when used for assessment of possible myocardial cell damage, need therefore 
probably not be different in dogs with stable CKD than in other dogs in a clinical 
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situation. The situation may be different for dogs with acute deterioration of 
renal function, regarding both NT-proBNP and cTnI.  
8.4.3 Glomerular filtration rate assessment  
The similar overall diagnostic value of SDMA, and the inferior diagnostic value 
of cystatin C, compared to creatinine indicate that creatinine can still be used as 
the first-line indirect marker of GFR.  Whether one marker or the other is able 
to detect decreased GFR at an earlier point in time during disease development, 
depends on where the cut-off value is placed. A low cut-off value will result in 
decreased specificity and more false positive results. Conversely, a high cut-off 
value will result in lower numbers of “falsely azotaemic” dogs, but the 
sensitivity of the test will be lower and some dogs with decreased GFR will be 
missed. Both SDMA and cystatin C have potential as complementary tests to 
creatinine however, especially for selected dogs. 
Creatinine concentrations should be interpreted with size of muscle mass of 
the dog in mind. If dogs are very small or have subnormal lean body mass (in 
which case use of a population-based reference interval is likely to result in 
decreased sensitivity of creatinine, or many false negatives) or large (in which 
case use of a population-based reference interval is likely to result in decreased 
specificity, or many false positives), the addition of another GFR marker such 
as SDMA or cystatin C concentration, may provide important additional 
information. As always, concerning estimations or calculations of GFR, any 
diagnosed decrease may represent a pre-renal, renal or post-renal, acute or 
chronic abnormality (or any combination of these). 
Even if a perfect biomarker for GFR was discovered, or if a perfect method 
for direct measurement of GFR was invented – the inherent variability and the 
resulting wide reference range of GFR itself has to be taken into account when 
aiming to diagnose a small decline in GFR following a single measurement in 
an individual dog. The decrease in GFR is also a comparably late event in the 
gradual nephron destruction cycle that characterises CKD, as noted in section 
8.3.2.  
8.4.4 Urinary capillary electrophoresis and mass spectrometry 
At present, there is no clinically available test that detects ongoing renal 
pathology at one point in time. Such tests are needed, and searched for, because 
of their potential for early diagnosis of progressive, or subclinically “active” 
disease. Urinary peptidomics analysis by CE-MS is a technique with potential 
as an adjunct diagnostic method for future non-invasive early diagnosis of CKD 
79 
 
in the dog. However, further validation of the diagnostic models 133P and 35P, 
described in paper IV, are necessary before possible future implementation.  
Although not yet commercially available, CE-MS is well suited for future 
clinical use because of high throughput and low cost of analysis (Schiffer et al., 
2012).   
8.4.5 Future perspectives 
During the work with this thesis (especially in the collaboration with human 
CKD researchers), difficulties with regard to the currently used definition of 
canine CKD became evident. An advantage with this definition is that it 
encompasses the whole spectrum of disease (unlike the terms “renal 
insufficiency” and “renal failure” that are imprecise, interchangeably used, and 
only refer to late stages of disease). A negative aspect of the current definition, 
however, is that individuals with non-progressive disease are included. In many 
dogs with a CKD diagnosis, this “disease” is not going to develop into a clinical 
problem throughout their lifetime.  
Some dogs that are diagnosed with stage 1 CKD may have a structural, non-
progressive, abnormality. Some have persistent renal proteinuria, which, even if 
present >3 months, may resolve. Thus, in addition to the dogs with non-
progressive, non-clinical disease, the current definition also may include dogs 
that are, at least clinically, “cured”. This may generate unnecessary confusion 
among owners of affected dogs and attending veterinarians. The labelling of a 
dog that has a non-progressive renal abnormality with a diagnosis of CKD may 
introduce unnecessary worry for owners and lead to a change in how the dogs 
are held, for example how the dog is exercised. Also, unnecessary and costly 
followup procedures have economic consequences for owners and insurance 
companies. Overdiagnosis is a term used in human medicine to describe a 
scenario in which the assignment of a diagnosis of disease leads to more harm 
than benefit for patients (Brodersen et al., 2018; Heneghan et al., 2017). 
A definition of canine CKD that includes only dogs with irreversible, 
progressive disease is needed. Progression, if not obvious at the time of the first 
examination, currently has to be confirmed by serial testing. During the time 
interval (even if > three months) from identification of a kidney-related problem 
to the time-point of confirmation of progression, the dog may be considered to 
be at risk for [progressive] CKD, rather than to be assigned a CKD diagnosis. In 
accordance, a new category may be introduced for dogs “at risk” for CKD. When 
progression is confirmed, the dog could be given a definitive diagnosis of CKD, 
and staged accordingly into IRIS stages 1 through 4. This suggested definition 
should be thoroughly evaluated for its clinical use before implementation. 
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Should a diagnostic test that reliably detects progression become available in the 
future (for example the urinary peptidomics approach with the 133P-model 
investigated in paper IV), it will probably facilitate diagnosis according to this 
definition.  
 
Table 2. Suggested clinical definition of canine CKD, including IRIS staging 
 
 
 
 
 
 
 
 
 
 
 
 
 CKD    
At risk Stage 1 Stage 2 Stage 3 Stage 4 
 
Structural or 
functional 
damage        
≥ 3 months 
 
Structural or 
functional 
damage        
≥ 3 months 
 
Progression 
confirmed 
 
Creatinine:       
<125 µmol/L 
< 1.4  mg/L 
 
Structural or 
functional 
damage        
≥ 3 months 
 
Progression  
confirmed 
 
Creatinine: 
125–180  
1.4–2.0   
 
Structural              
or functional 
damage        
≥ 3 months 
 
Progression 
confirmed 
 
Creatinine: 
180-440 
2.1-5.0 
 
Structural or 
functional 
damage            
≥ 3 months 
 
Progression 
confirmed 
 
Creatinine: 
>440 µmol/L 
> 5.0  mg/L 
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 The incidence rate of KD in a large population of insured Swedish dogs 
was 15.8 cases/10.000 DYAR. The kidney-related mortality rate was 
9.7 deaths/10.000 DYAR. The Bernese mountain dog was the breed with 
the highest incidence- and mortality rate of KD.  
 
 In dogs with and without CKD, the variables independently associated 
with NT-proBNP was PCV and PVF/kg, a factor related to extracellular 
fluid volume. Age, BW and SBP were the factors independently 
associated with cTnI concentration. Neither NT-proBNP nor cTnI 
concentrations were independently associated with mGFR. Results were 
not suggestive of passive accumulation of NT-proBNP or cTnI in 
clinically stable dogs with CKD. 
 
 Overall diagnostic performance of SDMA concentration as a marker of 
decreased GFR in dogs was similar to that of creatinine but better than 
that of cystatin C. Use of SDMA and cystatin C in addition to creatinine 
conveyed additional value for prediction of mGFR status in clinically 
stable dogs.  
 
 A model, 133P, was developed by CE-MS-based urinary peptidome 
analysis, and was shown to discriminate dogs with CKD from healthy 
dogs in a separate validation cohort (AUC = 0.88). Thirty-five out of the 
133 peptides contained in the model were sequenced, and most were 
identified as fragments of collagen I.  
 
 
 
 
9 Conclusions 
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10.1  Epidemiology of canine chronic kidney disease 
Further studies of incidence and mortality rates of CKD should be performed in 
other populations of dogs. Differences between breeds should be investigated in 
order to possibly confirm the high IRs in some breeds identified in paper I. 
Qualitative studies involving questionnaires directed at dog owners could 
possibly also contribute to knowledge regarding impact of KD in different dog 
populations.  
10.2  Cardiovascular biomarkers in kidney disease 
Interactions between the kidneys and the cardiovascular system in CKD need 
further investigation. The conclusion in paper II regarding GFR-independence 
of both NT-proBNP and cTnI should be confirmed in other populations of dogs 
with CKD, and in dogs with acute-on-chronic disease and AKI. A possible value 
of NT-proBNP concentration for estimation of circulating blood volume in some 
dogs with CKD (for example protein-losing nephropathy and nephrotic 
syndrome) is also called for. 
10.3  Indirect assessment of glomerular filtration rate 
Diagnostic performance of SDMA concentration as a marker of decreased GFR 
should be further studied in other populations of dogs. The interval LRs 
proposed in paper III needs further validation in such studies. The value of 
performing additional tests (SDMA and cystatin C concentrations) in dogs for 
which serum creatinine concentration is suspected to be a suboptimal test of 
GFR, should be prospectively investigated. 
10 Implications for future research 
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A new SDMA test for use in the clinic is released in 2018. Evaluation of the 
diagnostic performance of this benchtop analyser test as a marker of GFR in the 
dog is needed, especially in light of the high analytic variability shown for a 
variety of bench-top analyses of creatinine concentrations in one study (Braun 
et al., 2008). Additionally, RCV and individuality of SDMA (as well as 
creatinine and cystatin C) needs to be established, preferably by evaluating dogs 
of many different breeds and sizes. 
Cystatin C holds potential as a marker of GFR in the dog. The value of this 
test as an additional marker of GFR, using the proposed decision tree and the 
interval LRs proposed in paper III, needs further validation. A reference interval 
should be constructed for the cystatin C-analysis method used in paper III. The 
age-dependence of cystatin C identified in paper III should be further 
investigated in other populations.  
10.4  Urinary peptidomics 
Further validation of the diagnostic value of the 133P-model in other canine 
cohorts is necessary. Although a high repeatability has been shown for CE-MS 
analyses of human urine, repeatability for canine urine samples should be 
assessed. Variations, pre-analytical, analytical and biological variation highly 
affect clinical utility of an assay. Such investigations should include longitudinal 
studies of dogs with and without CKD.  
Specificity of the model needs to be addressed. The ability to distinguish dogs 
with CKD from dogs with other diagnoses is not known but should be 
investigated. This is especially important for diagnoses that are regarded 
differential diagnoses to CKD in a clinical situation, such as 
hyperadrenocorticism, diabetes insipidus or primary polydipsia. Early diagnosis 
of renal compromise by proteomic methods may be also complicated by changes 
that occur in renal ageing. Therefore, peptidomic models should be constructed 
to distinguish a pathological process from the aging process that is bound to 
occur. 
Investigation of the performance of the 133P-model in prediction of 
progression of canine CKD is to be performed. Should the 133P-model be able 
to detect the progressive fibrosing process itself, assessment of progression 
would be markedly facilitated in the clinic. 
Application of this technique for differential diagnosis of various aetiologies 
of CKD, potentially lessening the need for renal biopsy, is another future goal. 
Performing renal biopsy requires an invasive, expensive approach, carries a risk, 
and is therefore often not performed. In addition, the resulting small piece of 
tissue is not necessarily representative of the global tissue mass and the biopsy 
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procedure is seldom repeated for the reasons listed above. Value of the CE-MS 
approach in differentiating aetiologies of CKD has been shown recently in 
people (Siwy et al., 2016). Urinary peptidomics analysis may also be more 
representative of global tissue pathology compared to a biopsy specimen. An 
association between CE-MS peptide pattern and tissue histopathology has been 
demonstrated in one study (Magalhaes et al., 2017). Use of CE-MS in this 
respect has been proposed to represent a form of “liquid biopsy”. This should be 
studied in dogs as well, by comparing peptide patterns in urine from dogs with 
different specific aetiologies of CKD.  
Further identification and sequencing of peptides associated with 
development of canine CKD may provide insights regarding specific 
pathophysiologic events involved in progression. Identification of relevant 
proteases responsible for cleavage of fragments involved in the process of 
fibrosis could possibly lead to future studies of the efficacy of proteinase-
inhibitor treatment, as shown in a proof-of-concept study in people with diabetic 
nephropathy (Krochmal et al., 2017).  
Finally, it has been shown in people that the peptidomic profile changes in 
response to treatment (Andersen et al., 2010a). This could be investigated in 
dogs as well, because if it applies also for dogs, and if efficacy of the investigated 
treatment is proven, peptide profiling may represent a future tool for monitoring 
treatment with the target of “normalising” the peptide profile.  
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Chronic kidney disease (CKD), which is an important contributor to morbidity 
and mortality in dogs, is defined as the presence of structural or functional 
abnormalities in one or both kidneys for > three months. There are multiple 
aetiologies of CKD, but in many dogs the initiating cause is not evident (and 
may no longer be present) at the time of diagnosis. Clinical signs associated with 
decreased kidney function include loss of appetite and body weight, vomiting, 
and increased urine production and water intake. Current veterinary diagnostic 
methods are insensitive, and new markers for early disease detection are sought. 
The general aim of this thesis was to increase knowledge regarding 
pathophysiologic mechanisms and early diagnosis of canine CKD, by 
identifying dogs with increased risk of disease and by exploring the use of 
various biomarkers in blood and urine. 
Dogs are comparably commonly diagnosed with kidney-related disease 
(KD). A conservative estimate of the prevalence (percentage of dogs that are 
affected) of CKD has been suggested to be 0.5-1.5%.  Incidence (how many 
cases that are diagnosed) or mortality (how many deaths that occur) rates of KD 
are not known for either acute or chronic presentations. Such knowledge is, 
however, of practical use in clinic and research. Accordingly, the aim of paper I 
was to use data from a large animal insurance company database (Agria Animal 
Insurance) to estimate incidence and mortality related to kidney disease in a 
Swedish population of >600,000 insured dogs. The total incidence rate of kidney 
disease in this population was 15.8 cases per 10,000 dog years at risk (DYAR, a 
denominator representing one dog insured for one year). The breeds most 
commonly diagnosed with KD in this study were the Bernese mountain dog, 
miniature schnauzer and boxer. The Swedish elkhound, Siberian husky and 
Finnish spitz were the breeds least often diagnosed with KD. 
The cardiovascular system and the kidneys interact extensively in both health 
and disease. Increased concentrations in plasma or serum of two cardiovascular 
biomarkers, B-type natriuretic peptide (NT-proBNP) and cardiac troponin I 
11 Popular science summary 
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(cTnI), have been reported in dogs with decreased renal function. A passive 
accumulation of these markers in dogs with disease of the kidneys has been 
suggested. The aim of paper II was therefore to investigate if NT-proBNP and 
cTnI accumulate in dogs with CKD. Results presented in paper II do not support 
passive accumulation of these markers. Instead, the conclusion was that they 
identify pathophysiological events (increased blood volume and damage to 
cardiac cells, respectively) in some dogs with CKD.  
Considerable effort is directed at identification of new diagnostic circulating 
markers of decreased renal function (glomerular filtration rate, GFR) for 
widespread clinical use in veterinary medicine. Symmetric dimethyl arginine 
(SDMA) and cystatin C are two proposed biomarkers of decreased GFR in the 
dog. In paper III, the aim was to investigate overall diagnostic value of serum 
SDMA and cystatin C concentrations for detection of decreased GFR compared 
to the currently most commonly used marker, serum creatinine concentration. 
The overall diagnostic value of SDMA was equivalent to that of creatinine, but 
cystatin C performed less well as a marker of decreased renal function in this 
study. Combining markers appeared to be of diagnostic value for diagnosis of a 
decreased GFR. 
In human medicine, urinary peptidomics may be utilised to diagnose CKD at 
an early stage. A specific urinary peptide pattern (CKD273-model) that detects 
CKD has been developed and shown to be of value both for diagnosis of CKD 
and for prediction of deterioration of renal function over time in people. Changes 
in the canine urinary peptide pattern may represent a completely new 
opportunity for early diagnosis of CKD as well. The usefulness of urinary 
peptidomics as a diagnostic method has not previously been investigated in dogs. 
In paper IV, it was shown that a CE-MS-based urinary peptidome model, 133P, 
was able to discriminate healthy dogs from dogs with CKD in a separate 
validation-cohort. This model, although in need of further investigation and 
validation, represents an exciting new diagnostic modality, in that it may 
potentially detect chronic progressive CKD in a single urine sample.  
Results of the studies included in this thesis contribute with knowledge 
relevant to the diagnostic thought process in the evaluation of dogs with 
suspected kidney disease, and with new information regarding interactions 
between kidneys and the cardiovascular system. Also, a new diagnostic modality 
for CKD diagnosis is presented that may, if found useful in further studies, make 
a contribution to canine renal medicine in the future.  
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Kronisk njursjukdom (CKD) är en allvarlig sjukdom hos våra hundar. Många 
olika underliggande orsaker till CKD finns beskrivna. Då sjukdomen många 
gånger upptäcks jämförelsevis sent i sjukdomsförloppet är den exakta orsaken 
ofta inte möjlig att fastställa, eller åtgärda, vid tidpunkten för diagnos. De 
övergripande målen med denna avhandling var att öka kunskapen kring 
patofysiologiska mekanismer vid, och tidig diagnostik av, CKD hos hund.  
Njursjukdom förekommer förhållandevis ofta hos våra hundar, men uppgifter 
saknas avseende hur ofta njursjukdom diagnosticeras och hur ofta det leder till 
att hundar dör. I studie I sammanställdes data från > 600 000 hundar registrerade 
hos Agria Djurförsäkring under en tolvårsperiod (1995-2007). Förekomst av, 
samt dödlighet till följd av, njursjukdom undersöktes. Förekomsten beräknades 
till ca 16 nya fall per 10 000 hundår (ett mått som innebär en hund försäkrad 
under ett år). Dödligheten till följd av njursjukdom uppgick till ca 10 dödsfall 
per 10 000 hundår. Information togs även fram för de i databasen vanligast 
förekommande raserna. Högst förekomst av njur-relaterad sjukdom sågs hos 
berner sennen, dvärgschnauzer och boxer. Lägst förekomst sågs hos jämthund, 
siberian husky och finsk spets. Många raser kunde dock inte inkluderas i denna 
jämförelse, på grund av ett för litet antal försäkrade hundar inom rasen. 
B-type natriuretic peptide (NT-proBNP) och hjärtspecifikt troponin I (cTnI) 
utgör två sjukdomsmarkörer som kan mätas i blodet och används för att upptäcka 
ökad cirkulerande blodvolym respektive hjärtmuskelcellskada hos hund. 
Tidigare studier har visat att höga koncentrationer av dessa markörer kan ses i 
blodet hos hundar med njursjukdom.   Orsaken till detta har inte varit känd. En 
passiv ackumulering av dessa ämnen i blodet, vilket skulle medföra att deras 
diagnostiska värde för detektion av hjärt- och kärlpåverkan minskar har tidigare 
inte kunnat uteslutas, och detta undersöktes i studie II. Resultaten indikerade 
frånvaro av passiv ackumulering i blodet, och slutsatsen var att dessa markörer 
indikerar hjärtmuskelcellskada och ökad cirkulerande blodvolym hos hundar 
såväl med som utan CKD.  
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Inom veterinärmedicinen pågår ett ständigt sökande efter nya diagnostiska 
metoder för detektion av nedsatt njurfunktion i ett tidigt skede. Symmetrisk 
dimethylarginin (SDMA) och cystatin C är två potentiella markörer som kan 
användas för detektion av nedsatt njurfunktion. I studie III jämfördes det 
diagnostiska värdet av dessa markörer, jämfört med värdet av den markör som 
används sedan länge för diagnos av nedsatt njurfunktion; koncentrationen av 
kreatinin. Det visade sig att det övergripande diagnostiska värdet av SDMA för 
diagnos av nedsatt njurfunktion var likvärdigt med värdet av kreatinin. Det 
övergripande värdet av cystatin C för diagnos av nedsatt njurfunktion var dock 
lägre än värdet av de båda andra markörerna. För vissa hundar finns dock 
troligen ändå anledning att analysera koncentrationer av SDMA eller cystatin C 
förutom koncentrationen av kreatinin, för att erhålla en förbättrad utvärdering av 
njurfunktionen. 
I studie IV utvärderades en helt ny metod (kapillär elektrofores och 
masspektometri, CE-MS), för diagnosticering av njursjukdom. Med hjälp av 
denna metod undersöks urinens hela innehåll av proteinfragment, så kallade 
peptider. Skillnader i peptidmönster mellan sjuka och friska individer 
undersöktes i studien och en statistisk modell, 133P, för diagnostik av CKD 
konstruerades. Validering av 133P-modellen i en separat grupp av hundar med 
och utan CKD visade att modellen kunde särskilja dessa grupper. Urinanalys 
med hjälp av CE-MS behöver valideras ytterligare, men utgör ett spännande nytt 
diagnostiskt alternativ för tidig diagnostik av CKD hos hund i framtiden.  
Resultat från de studier som ingår i denna avhandling bidrar med kunskap 
som kan vara till nytta i den diagnostiska tankeprocessen samt med ökad 
förståelse för hjärt- och kärlpåverkan hos hundar med CKD. Dessutom 
presenteras en ny diagnostisk metod som, om den håller måttet vid utvärdering 
i framtida studier, potentiellt kan komma att göra stor skillnad inom veterinär 
njurmedicin i framtiden. 
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